

Professor Alison L Jones

BSc(Hons) Med Sci, MD, FRCPE, FRCP, CBiol FRSB, FRACP, FACMT, FAACT, GAICD

Contact

Mobile: [REDACTED]

Email: [REDACTED]

LinkedIn: [linkedin.com/in/alison-jones-52838259](https://www.linkedin.com/in/alison-jones-52838259)

Achievements

Australian Learning and Teaching Council (ALTC) Grant (2010)

“Enhancing the teaching of medication safety to nursing, pharmacy and medical students through interprofessional education”

Levett-Jones T, Bellehambers H, Gillighan C, Stone T, Outram S, Cooper J, Rasiah R, Jones AL, Peterson G. Collaboration between University of Newcastle, University of Western Sydney and UTas.

National Health Service (UK)
Consultant Clinical Excellence Bronze Merit award (2010)

European Science Foundation Grant for conference attendance (1997)

European Association of Poisons Control Centres and Clinical Toxicologists Research Prize (1996)

European Science Foundation Grant for conference attendance (1995)

Lewis Cameron Postgraduate Prize for Medicine - University of Edinburgh (1994)

Oxford University Postgraduate Scholarship for Internal Medicine course attendance (1993)

Royal College of Physicians (London) Scholarship for Advanced Medicine Course (1992)

Career Summary

- Director of Medical Education across major teaching hospitals in South Perth – a strategic role using education to change quality of care and empower research.
- Acting Chief Medical Officer, Department of Health, Western Australia – a strategic role at health systems level
- Concurrently held the positions of Deputy Vice-Chancellor (Health and Communities) and Executive Dean, Science, Medicine and Health, at the University of Wollongong. Acting Vice-Chancellor.
- Head of Medicine at London’s Guy’s and St Thomas Hospital and Director of National Poisons Information Service (2000 –2006)
- Clinically active to uphold medical speciality qualifications and continue clinical research and teaching. Highly regarded toxicology researcher whose work has changed clinical practice

Serves as a high-level toxicology adviser to both Commonwealth and State Government agencies

Academic Qualifications

- 2019 Graduate of the Australian Institute of Company Directors (GAICD)
- 2018 Membership of the Australian Institute of Company Directors (MAICD)
- 2013 Fellow of the American Academy of Clinical Toxicology (FAACT)
- 2013 Fellow of the American College of Medical Toxicology (FACMT)
- 2010 Australian Health Practitioner Regulation Agency (AHPRA) registered Specialist Physician (MED0001193984)
- 2008 Fellow of the Royal Australasian College of Physicians, and recognition as a specialist physician in Australia (FRACP)
- 2006 NSW Medical Board, Australia registered practitioner (MPO 345247)
- 2002 Fellow of the Royal College of Physicians of London (FRCP)
- 2000 Certificate in Teaching, University of London
- 2000 Certified Biologist and Fellowship of the Royal Institute of Biology, London (CBiol, FRSB)
- 1999 Fellow of the Royal College of Physicians of Edinburgh (FRCPE)
- 1998 European Registered Toxicologist (ERT) (5 years)
- 1997 Certificate of Completion of Specialist Training (CCST) in General (Internal) Medicine, UK
- 1997 General Medical Council (GMC) Registered Specialist (3326318), UK Not currently licensed in UK as working abroad
- 1996 Doctor of Medicine (PhD equivalent) University of Edinburgh
Thesis: Invasive haemodynamic studies in cirrhosis
- 1992 Membership of the Royal Colleges of Physicians MRCP (UK)
- 1989 Bachelor of Medicine and Bachelor of Surgery
University of Edinburgh
- 1986 Bachelor of Medical Science (Honours) Biochemistry Upper Second Class
University of Edinburgh

Professional Experience

Director of Medical Education (1.0 FTE until December 2021, then 0.2FTE concurrent with A/CMO role, and 1.0 FTE from September 2022 to present) including consultant physician (general internal medicine) and clinical toxicologist	Fiona Stanley and Fremantle Hospitals Group, and South Metropolitan Area Health Service, Perth, Western Australia	February 2021-present
Acting Chief Medical Officer (0.8 FTE)	Department of Health, Western Australia	December 2021-September 2022
Deputy Vice-Chancellor (Health & Communities) (1.0 FTE)	University of Wollongong, Australia	Oct 2017 – February 2021
Executive Dean, Science, Medicine & Health Faculty (1.0 FTE)	University of Wollongong, Australia	Dec 2013 – February 2021
Clinical Academic in General Medicine (0.2 FTE) – The Wollongong Hospital	Illawarra Shoalhaven Local Health District (ISLHD), Wollongong, Australia	Jul 2014 – February 2021
Staff Specialist in Clinical Toxicology (0.1 FTE) – Blacktown Hospital	Western Sydney Local Health District (WSLHD), Wollongong, Australia	Aug 2011 – February 2021
Pro Vice-Chancellor (Health Strategy) (1.0 FTE)	University of Wollongong, Australia	Apr 2016 – Oct 2017
Dean of Medicine, Graduate School of Medicine (1.0 FTE)	University of Wollongong, Australia	Jun 2011 – Jun 2014
Dean, School of Medicine (1.0 FTE)	University of Western Sydney, Australia	Sep 2009 – May 2011
Staff Specialist in General Medicine (0.2 FTE) – Maitland Hospital	Hunter New England Area Health (HNELHD), Australia	Nov 2009 – Aug 2014
Professor of Medicine and Clinical Toxicology	University of Newcastle, Australia	Nov 2006 – Sep 2009
Clinical Academic Specialist in General Medicine and Clinical Toxicology	Calvary Mater and John Hunter Hospitals, Australia	Nov 2006 – Sep 2009
Consultant Physician and Clinical Toxicologist, National Poisons Information Service, Director for 3 years	Guy's and St Thomas' Hospital, London, United Kingdom	Oct 1998 – Nov 2006
Honorary Senior Lecturer in Clinical Pharmacology	University of London, United Kingdom	Oct 1998 – Nov 2006
Head of Medicine at major teaching hospitals	Guy's and St Thomas' Hospitals, London, United Kingdom	Oct 2000 – Oct 2003
Director, Medical Toxicology Unit Including National Poisons Information Service (London), Veterinary Poisons Service, Clinical Toxicology Service and Medical Toxicology Unit Laboratories	Guy's and St Thomas' Hospitals, London, United Kingdom	Mar 2003 – Nov 2006
SEARO WHO Collaborating Centre For Clinical Toxicology, London	Guy's and St Thomas' Hospitals, London, United Kingdom	Oct 2000 – Nov 2006
Acting Director of Scottish Poisons Information Bureau and Consultant Physician	Royal Infirmary of Edinburgh NHS Trust, Scotland	Mar 1998 – Oct 1998
Senior Registrar in General Medicine, with an interest in Clinical Toxicology, Environmental Toxicology and Poisons Information Services	Royal Infirmary of Edinburgh NHS Trust, Scotland	Oct 1993 – Mar 1998

Clinical Research Fellow, Department of Medicine	University of Edinburgh, Scotland	Oct 1992 – Sep 1993
Senior House Officer 3 in General Medicine (Registrar Duties) Wards 29/30	Royal Infirmary of Edinburgh NHS Trust, Scotland	Feb 1992 – Sep 1992
Senior House Officer Rotation in Medicine Borders General Hospital, Wards 26/27 Coronary Care Unit	Royal Infirmary of Edinburgh NHS Trust, Scotland	1990 - 1992
Pre-Registration House Officer Appointments General Surgery, Wards 9 and 10 General Medicine, Wards 29 and 30	Royal Infirmary of Edinburgh NHS Trust, Scotland	1989 - 1990

DEPARTMENT OF HEALTH, PERTH, AUSTRALIA

Acting Chief Medical Officer Western Australia

December 2021-present

Strategic and operational responsibility for health systems leadership

- Enabling strategic partnerships with Health Service Providers, Universities, and working across the WA Health Department
- Design and delivery of new models of engagement with director of clinical services across WA to provides health systems assurance and governance. Briefing notes HEC and direct liaison with CEOs of hospitals, heads of departments, Royal Colleges, WAPHA, .
- Advice and support to Ministers across a wide range of health issues
- COVID-19 preparedness and support of clinical systems e.g. oral antivirals
- Advising and optimising high level clinical governance and outcomes
- Serving on Quarantine Advisory Panel for WA Govt
- Strategic advice on workforce issues e.g. WA psychiatry workforce strategic plan,
- Ministerial delegated authority e.g. organ transplantation
- Support for PMCWA and VAD
- Toxicology advice provision and leadership

FIONA STANLEY AND FREMANTLE HOSPITALS GROUP AND SMHS, PERTH, AUSTRALIA

Director of Medical Education

Feb 2021-present

Strategic and operational responsibility for education and research leadership

- Enabling strategic partnerships with Universities, Health and Medical research institutes and WA Health Department, especially PMCWA
- Strategic partnership in design and delivery of new “clinical school” model
- Support to introduce virtual reality training into SMHS
- Optimising accreditation, pastoral support and education of senior and junior doctors including new leadership programmes, competency frameworks for heads of specialties
- Advising and optimising high level clinical governance and outcomes e.g. PCH review implications for SMHS
- Serving on Quarantine Advisory Panel for WA Govt; presenter at WA Clinical Senate
- Enabling research strategic leadership including with Fiona Wood, Merrilee Needham and Fiona Stanley and Aboriginal research (with corporate sponsorship)
- Toxicology advice provision and leadership

UNIVERSITY OF WOLLONGONG, AUSTRALIA

Deputy Vice-Chancellor (Health & Communities)

Oct 2017 – February 2021

Pro Vice-Chancellor (Health Strategy)

Apr 2016 – Oct 2017

The Deputy Vice-Chancellor (Health & Communities) portfolio encompasses senior executive leadership at whole of UOW together with specific leadership of UOW’s cutting edge health strategies. The DVC(HC) is responsible for the academic oversight and overarching strategic future direction of UOW’s regional and metropolitan campuses as well as the Inclusion and Outreach portfolio, incorporating the Woolyungah Indigenous Centre.

- Conceptualised implemented the UOW Health Strategic Plan (2016) and UOW Health and Wellbeing Strategy (2014) including \$400-\$500M (Phase 1 & 2) Health and Wellbeing Precinct on UOW Innovation Campus

- Established new full sized nursing school at South West Sydney Liverpool campus (target 700 students) in partnership with SWSLHD, WSU, the Ingham Institute and UNSW in a complex and competitive environment
- Spearheaded the development of \$80M Molecular and Life sciences “Molecular Horizons” Facility centred around electron microscopy (cryo-EM) and confluent technologies
- Launched the “Mind the GaP facility” - a multi-partner (Lifeline, Shoalhaven Council, IHMRI, ISLHD) suicide prevention, trauma recovery, mental health research and enhanced community resilience centre at Shoalhaven Campus
- Active member of the UOW Crisis Management Team and beyond in response to the whole of university challenges posed by COVID-19
- Provided senior leadership in UOW response to 2020 bushfires, followed by the development of philanthropic NSW and National bushfire resilience bids, in response to the bushfire crisis coordinating support across eight Australian Universities

UNIVERSITY OF WOLLONGONG, AUSTRALIA

Executive Dean, Faculty of Science, Medicine and Health

May 2014 – February 2021

Acting Executive Dean, Faculty of Science, Medicine and Health

Dec 2013 – May 2014

The Executive Dean, Faculty of Science, Medicine and Health (SMAH) undertook strategic and operational leadership of a newly formed faculty at a time of major and exciting transformational change for the University. SMAH brings together part of the former Science Faculty, Health and Behavioural Sciences and the Graduate School of Medicine. This is a broad-based faculty bringing together the disciplines of biology, chemistry, earth and environmental sciences (including geology and archaeology), Indigenous health, medicine, nutrition and dietetics, exercise sciences and nursing.

- Led complex change management process following external review of science schools (Biology, Chemistry and Earth & Environmental Sciences) resulting in realignment into School of Chemistry and Molecular Bioscience (SCMB) and School of Earth, Atmospheric and Life Sciences (SEALS)
- Implementation of emergency remote online teaching in response to COVID-19 whilst ensuring a strong sense of collegial culture and identity within the faculty and every faculty interface internally and externally
- Demonstrated growth in student numbers year on year to exceed targets and strong financial management of approximately \$65M Faculty budget (\$125M income) at a time of intense fiscal tightening across the sector
- Secured \$30M+ of Commonwealth funding for a National Dementia Training Centre
- Assisted in securing \$32M of funding for the ARC Centre of Excellence for Australian Biodiversity and Heritage (CABAH) and \$5M OEH Bushfires Hub
- Developed SMA vision statement and overall strategy, incorporating new teaching and learning strategies, curriculum transformation and research growth while developing a new cross-school faculty culture
- Oversaw the development of the UOW Indigenous Trauma Recovery Programme
- Extended SMAH international presence across India and China and delivering nursing programmes into UOW Hong Kong and UOW Dubai

BLACKTOWN HOSPITAL, WESTERN SYDNEY LOCAL HEALTH DISTRICT (WSLHD)

Staff Specialist in Clinical Toxicology

Aug 2011 – February 2021

- Toxicology on-call via telephone for fixed 24 hour period per week (Tuesday) with post-take clinical ward round the following morning
- This work as a Staff Specialist in Clinical Toxicology provides the opportunity to:
 - uphold clinical toxicology skills
 - teach specialty toxicology trainees and medical students
 - attend clinical toxicology case and international meetings to maintain Continuing Professional Development
 - continue clinical toxicology research (SMS SOS text message study to reduce self-harm, e-cigarettes, drugs, assaults)
 - work alongside CIO WSLHD in trialling information tech solutions into clinical practice e.g. e-prescribing, e-medical records, e-research and SMS text message study

THE WOLLONGONG HOSPITAL, ILLAWARRA SHOALHAVEN LOCAL HEALTH DISTRICT (ISLHD)

Clinical Academic in General Medicine

Jul 2014 – February 2021

- Acute General Medicine on-call via telephone for fixed 24 hour period two days per month with post-take ward round the following day
- This work as a Clinical Academic in General Medicine provides the opportunity to:
 - uphold medical skills to undertake clinical research
 - teach medical registrars/nurses/medical students as well as health and nursing students on rounds and in tutorial
 - enhance credibility when liaising with health stakeholders

- maintain minimum 150 hours of continued professional development per year, registered with the Royal Australasian College of Physicians (RACP)

UNIVERSITY OF WOLLONGONG, AUSTRALIA

Dean of Medicine, Graduate School of Medicine (GSM)

Jun 2011 – Jun 2014

The Dean of Medicine role was one of strategic and operational leadership of a new School of Medicine (established in 2007, first graduates 2011) delivering an innovative case-based and online educational programme in the context of the whole university, and its health and community partners. The Graduate School of Medicine (GSM) partners with others to engage in community focussed health activities.

- Led the restructure of the medical school with a focus on accountability leadership and the successful integration of three new health disciplines; Indigenous Health, Medical & Exercise Sciences and Nutrition & Dietetics
- Increased student numbers from 400 to 2,500 following the introduction of the three new health disciplines
- Educated on research development, challenged unwanted behaviours, reinforced a whole of team view and provided new impetus for change in recruitment, staff development, promotions, research and innovative digital and face-to-face learning and teaching
- Increased additional philanthropic income for the school through development of new strategies
- Advanced rural and remote hubs including oversight of submissions to Government and other major bodies
- Oversaw the AMC full accreditation of the GSM through meticulous quality assurance on teaching activities
- Pursued Singapore and Malaysian Council accreditation through visits to both countries
- Appointed as Deputy Executive Director (Clinical) for the Illawarra Health and Medical Research Institute (IHMRI)
- Jointly responsible for IHMRI policy development, strategic oversight and higher level operational activities of the Institute together with strengthening regional, national and global connections

UNIVERSITY OF WESTERN SYDNEY, AUSTRALIA

Dean, School of Medicine

Sep 2009 – May 2011

Dean, School of Medicine role was responsible for the strategic leadership and operational management of the new School of Medicine.

- Administrative leadership for the School of Medicine – 156 staff, 600 medical students, 40 PhD students
- Authored "Unobstructed Views" the School of Medicine's strategic vision document and 5 year strategic roadmap
- Developed and consolidated years 3-5 of the Medical School undergraduate MB BA, MBBS/BA and MB BS/PhD programme – academic, financial and community engagement leadership
- Growth of new business – postgraduate medical education, development of new research activities across the School of Medicine using seed funding, new business opportunities
- Enhanced development of two rural clinical schools under the Commonwealth funding initiative, and their teaching programme in Lismore and Bathurst – capital works programmes, educational programs, staffing, student support
- Led "Heartstart" - a community engagement project for children in years 4 and 5 to improve health literacy, enhance consideration of health careers and improve community engagement and links
- Development and consolidation of UWS clinical schools at Blacktown, Campbelltown and Liverpool Hospitals
- Conceptualised and wrote successful bid for \$4 million HWA bid for ICTC interdisciplinary training project
- Advanced indigenous medical education through student support, bridging courses and indigenous health experience for every medical student at UWS via partnership arrangements with Aboriginal Medical Services
- Development of the Ingham Institute of Medical Research in collaboration with UNSW and Liverpool Hospital – buildings, protocols, development of MRI- Linac facility. Served as Board Member and Chair of the Scientific Committee

MAITLAND HOSPITAL – HUNTER NEW ENGLAND LOCAL HEALTH DISTRICT (HNELHD)

Staff Specialist in General Medicine

Nov 2009 – Aug 2014

- Staff Specialist at Maitland Hospital providing hands on acute general medicine, with unselected medical "take" and ongoing care of patients for 48-96 hours (with effective handover thereafter)
- This work as a Staff Specialist provides the opportunity to:
 - teach interns/medical registrars/nurses/medical students (UoN)/allied health and nursing students on rounds and in tutorial
 - maintain more than 150 hours of continued professional development per year, which is registered with the Royal Australasian College of Physicians (RACP)

UNIVERSITY OF NEWCASTLE, AUSTRALIA**Professor of Medicine and Clinical Toxicology****Nov 2006 – Sep 2009****Head of Academic Disciplines of Clinical Pharmacology and General Medicine****Mar 2007 – Sep 2009**

Responsible for the design and implementation of multidisciplinary research programmes in clinical toxicology and medicine.

- Administrative lead for department of clinical pharmacology overseeing 22 staff
- Lead for BMED programme pre-intern course year 5
- Chair of Year 4 BMED program and Joint Medical Program with the University of New England
- Head of discipline across the clinical pharmacology curriculum and general medicine (Mater hospital)
- Senior member of two Priority Research Centres; Health Behaviours and Organic Electronics (Chemistry and Physics)
- Program convener for UoN distance-learning postgraduate programme in Clinical Toxicology

CALVARY MATER & JOHN HUNTER HOSPITALS – HUNTER NEW ENGLAND LOCAL HEALTH DISTRICT (HNELHD)**Clinical Academic Specialist in General Medicine and Clinical Toxicology****Nov 2006 – Sep 2009**

- General medicine and 3 months of clinical toxicology each year - initially high intensity
- On call for general medicine and clinical toxicology on an area wide basis (every Monday 24 hours and 1 in 4 weekends)
- Foundation Chairman of the Hunter New England Area Quality Use of Medicines Committee
- Consultant toxicologist to the NSW Poisons Information Centre, actively participating in the National Poisons advice roster for Australia

GUY'S AND ST THOMAS' HOSPITALS, LONDON**Consultant Physician and Clinical Toxicologist****Oct 1998 – Nov 2006****Head of Medicine****Oct 2000 – Oct 2003****Director, Medical Toxicology Unit Including National Poisons Information Service (London), Veterinary Poisons Service, Clinical Toxicology Service and Medical Toxicology Unit Laboratories****Mar 2003 – Nov 2006**

Guy's and St Thomas' Hospital NHS Trust is the largest and most successful teaching hospital in the UK. During my time here I conceived, developed and became lead consultant for the Clinical Toxicology Service, which reviews the care of all poisoned patients in St Thomas' Hospital. I also developed tertiary referral combined care with ITU staff for seriously poisoned patients from other hospitals in London.

- **Director of the Medical Toxicology Unit at Guy's Hospital (2003 – 2006)**
 - Led the National Poisons Information Service (London) Centre, the Veterinary Poisons Service, the MTU Laboratories (research and clinical) and Clinical Toxicology Service
 - Collaborated with a number of government agencies and departments including the Health Protection Agency, the Department of Health, Metropolitan Police, Cabinet Office and Defence Services
 - Operational management of 89 members of staff
 - Oversaw the planning and design of the London Integrated Toxicology Centre building
- **Head of Medicine (2000 – 2003)** (also Deputy Clinical Director across the whole Acute Medicine Division at the Trust ED, ICU, medicine and subspecialties).
 - Managed £68 million per annum budget and more than 400 staff
 - Member of senior leadership team at the Trust and operationally responsible for management of clinical colleagues
 - Liaison between different disciplines, clinical and non-clinical services at hospitals and multiple external stakeholders
 - Capacity built for teaching and research opportunities together with the postgraduate Dean University of London
 - Held strong clinical governance role managing poorly performing consultant colleagues sensitively but effectively
 - Strategically led and successfully achieved the NHS 4 hour ED targets by redesigning the patient's journey of care
 - Oversaw the effective merger of two (previously divisive) divisions of medicine of Guy's and St Thomas
 - Participated in the strategic work (in partnership with McKinseys) around redesign and re-evaluation of the future of general medicine and specialist medicine at Guy's and St Thomas'
 - Completed "Leading for change" change management training program at the Trust

**WHO SEARO (WORLD HEALTH ORGANISATION SOUTH-EAST ASIA REGIONAL OFFICE)
COLLABORATING CENTRE FOR CLINICAL TOXICOLOGY, LONDON****London Collaborating Centre Director****March 2003 – Nov 2006****Committee Member****Oct 2000 – Nov 2006**

WHO SEARO provides leadership on health matters, articulates evidence-based policy options, provides technical support to countries and monitors health trends.

- Core member of the World Health Organisation / International Programme on Chemical Safety INTOX project, including visiting lecture programme on clinical toxicology to less well developed countries
- Provided advice to WHO in handling acute incidents where toxins may be involved (Ethiopia in 2009 with a hepatotoxicity incident) and advice to UN (Dr John Haines)
- Assisted WHO and international colleagues with poisons specialist education and research strategies

Board Leadership

2019 – ongoing	Illawarra Health & Medical Research Institute (IHMRI)	Director
2015 – ongoing	Coordinare (Primary Health Network) <ul style="list-style-type: none"> ▪ Nominations Committee ▪ Clinical Governance Committee 	Director
2011 – ongoing	Medical Deans of Australia and New Zealand (MDANZ) <ul style="list-style-type: none"> ▪ MSOD Board ▪ GAMSAT Board ▪ Indigenous Subcommittee (Chair) 	Director & Secretary
2010 – 2011	Ingham Institute for Medical Research (IIMR) <ul style="list-style-type: none"> ▪ Scientific Committee Chair 	Director
2006 – 2016	Australian Strategic Policy Institute (ASPI) <ul style="list-style-type: none"> ▪ Audit & Risk Committee 	Director and Board Member
2000 – 2006	Royal College of Physicians of Edinburgh (RCPE) <ul style="list-style-type: none"> ▪ President’s Advisory Group 	Member of Council
1994 – 1997	Royal College of Physicians of Edinburgh (RCPE) <ul style="list-style-type: none"> ▪ Collegiate Member’s Committee 	Member of Council

Expert Advisory Roles

2019 – ongoing	OUTBREAK Advisory Board
2013 – ongoing	Ministerial Advisory Committee on Preventive Health (NSW)
2012 – 2018	RCPE Regional Adviser for NSW, ACT and Queensland
2007 – ongoing	High level toxicology adviser to NSW Health
2007 – 2009	Hunter New England Health Area Quality Use of Medicines Committee(HNELHD) – Chair
2007 – 2009	NSW Therapeutic Advisory Group Member
2000 – 2003	Human Section of the British Toxicology Society - Chair
1999 – 2006	RCPE Regional Adviser for Greater London
1998 – 2006	Member of the Scientific Committee of the British Toxicology Society
	Coroners (NT, NSW and ACT) adviser on confidential toxicology matters
	Food Standards Australia New Zealand (FSANZ) adviser on confidential toxicology matters
	Commonwealth and State Government agencies toxicology expert and strategic planning adviser
	Glaxo Smith Kline (Global) scientific adviser
	Delivered lectures on chemical terrorism protection and resilience in Australia and the USA at the invitation of the Prime Minister’s and Cabinet Office
	Prime Minister’s 2020 Summit attendee in Canberra (2008), serving in the “Global and Security Stream”

Appendix to CV – academic outputs

Higher Degree Research (HDR) Completions

Name	Title	University, degree and completion date
------	-------	--

Victor Hallequist Principal supervisor 100%	GISETTO (genes in serotonin toxicity)	MSc by research University of Uppsala Completed 2008
Amanda J Wilson Principal supervisor 50%	Assessing the quality of health news stories in the Australian media using the Media Doctor website	University of Newcastle PhD Completed October 2010
Marie-Clare Hogue Co-supervisor	Pharmaceutical production; productive or problematic for public health	University of Newcastle PhD Completed December 2012 Accepted with minor revisions
Tharaka Dassanayake Co-supervisor	The neurocognitive dysfunction after overdose of sedative drugs	University of Newcastle PhD Winner of the Faculty RHD outstanding publication prize The University of Newcastle PhD Scholarship Endeavour Scholarship. Completed June 2012
Garry Stevens Co-supervisor	Risk and resilience factors predicting terrorism threat perception and anticipatory behaviours in three differentially exposed groups: general population, emergency service workers and survivors of terrorism.	University of Western Sydney PhD completed
Kate O'Hara Co-supervisor	Drug metabolism and pharmacodynamic alterations in neonates who undergo cooling	University of Newcastle Part-time PhD current Passed confirmation stage December 2012
Stewart Oxley Co-supervisor	Follow up of patients after discharge with drug overdose – TMTB	University of Newcastle Masters by Research in psychology Completed 2015.
Kerrie Burton Primary supervisor	Respiratory protection against diesel particulate exposures	University of Wollongong Masters by Research Completed 2016 – current Now transitioning to a PhD
Jane Whitelaw	Workers respiratory protection and physiological responses to heat.	University of Wollongong PhD ongoing

Current EFTSL research supervision load approximately 1.8

Research Grants/Contracts Awarded

Funding Source	NHMRC – Project Grant (1161581)
Title	Effect of exposure to fluoridated water in early childhood on child psychological and intellectual development
% Time and my role	5% - toxicological expertise; AJ = co-CI = \$0
Chief Investigator	Prof Loc Do, University of Adelaide
Total Funds (\$)	\$828,756.90
Period	2019 – 2021 (3 years)
Funding Source	UOW SMAH Small Project Grant – Health and Medical Collaborative Grant
Title	Are all e-cigarette fluids created equal? Analytical comparison of the content of e-fluids currently available to Australian consumers
% Time and my role	5% - toxicological expertise; AJ = co-CI
Chief Investigator	Dr Jody Moller & Dr Celine Kelso, University of Wollongong
Total Funds (\$)	\$19,000
Period	2019 (1 year)
Funding Source	NHMRC – Partnership Grant (1113396)
Title	Does Omega-3 supplementation attenuate aggressive behaviour: a multi-centre randomised controlled trial of a broadly disseminable strategy
% Time and my role	AJ = co-CI(D) = \$0
Chief Investigator	A/Prof Barbara Meyer, University of Wollongong
Total Funds (\$)	\$845,278
Period	2016 – 2020 (5 years)
Funding Source	NSW Health
Title	SMS SOS: Using SMS text messages to prevent self-harm
Chief Investigator	Prof Alison L Jones, University of Wollongong
Total Funds (\$)	\$330,000
Period	2016 – 2017 (2 years)
Funding Source	NSW Health
Funding Source	Horticulture Innovation Australia (HIA) Ltd; Strategic Co-Investment Pool; Green Cities Fund (GC15005)
Title	Greener cities healthier lives: measuring the wider social benefits
Chief Investigator	Dr Xiaoqi Feng, University of Wollongong; AJ = co CI = \$0
Total Funds (\$)	\$3,279,176
Period	Sept 2016- Sept 2021 (5 years)
Funding Source	Horticulture Innovation Australia (HIA) Ltd; Strategic Co-Investment Pool; Green Cities Fund (GC15005)
Funding Source	University of Wollongong – UOW Global Challenges
Title	Greener cities healthier lives
Chief Investigator	Dr Xiaoqi Feng, University of Wollongong; AJ= co CI =\$0
Total Funds (\$)	\$30,000
Period	2016 (1 year)
Funding Source	University of Wollongong – UOW Global Challenges
Funding Source	Coal Services Health and Safety Trust
Title	Respiratory Protection – Are our standards protecting worker health or providing a false sense of security?
% Time and my role	Student supervision : AJ = co-CI
Chief Investigator	Jane Whitelaw, University of Wollongong
Total Funds (\$)	\$48,075
Period	2015 (1 year)
Funding Source	Workcover Authority of NSW – Applied Research Grant
Title	Respiratory Protection – Are our standards protecting worker health or providing a false sense of complacency?
% Time and my role	Student supervision: AJ = co-CI
Chief Investigator	Jane Whitelaw, University of Wollongong
Total Funds (\$)	\$39,995.40
Period	2015 (1 year)
Funding Source	NSW Ministry of Health
Title	Provision of high level toxicology advice on a 24/7 basis
% Time	5% - sole delivery
Chief Investigator	Professor Alison Jones, University of Wollongong
Total Funds (\$)	\$195,800
Period	2015-2019 (5 years)
Funding Source	NSW Ministry of Health
Title	Provision of high level toxicology advice on a 24/7 basis
% Time	5% - sole delivery
Chief Investigator	Professor Alison Jones, University of Wollongong
Funds (\$)	\$135,000
Period	2012-2014 (3 years)

Funding Source	NHMRC – Centre of Research Excellence (1030259)
Title	Understanding and ameliorating the human health effects of exposure to air pollution from knowledge to policy and public health practice.
% Time and my role	10% study design, ethics submission, study protocols, implementation, data analysis and write up: AJ = co-CI(G) = \$0
Chief Investigator	Marks G, University of Sydney
Total Funds (\$)	\$2,411,828
Period	Jan 2012-Dec 2017 (6 years)
Funding Source	NHMRC – Project Grant (1029815)
Title	An olfactory “stress test” for early detection of Alzheimer’s Disease
% Time and my role	10% Drug trial and design, data interpretation, pharmacology and safety: AJ = co-CI = \$0
Chief Investigator	Schofield P, University of Newcastle
Total Funds (\$)	\$743,450
Period	Jan 2012- Dec 2014 (3 years)
Funding Source	Australian Teaching and Learning Council (ALTC)
Title	Enhancing the teaching of medication safety to nursing, pharmacy and medical students through interprofessional education
Top 3 Investigators	Levett-Jones, Bellchambers, Gillighan et al, University of Newcastle/University of Western Sydney/University of Tasmania
Total Funds (\$)	\$217,000
Period	2010-2011 (2 years)
Funding Source	Australian Teaching and Learning Council (ALTC)
Funding Source	Bellberry Limited
Title	SMS SOS: A RCT of the efficacy of SMS text messages in reducing representation of deliberate self-poisoning patients
% Time and my role	25% - study design, CIA leading ethics submission, study protocols, implementation, data analysis and write up : AJ = CI(A)
Top 3 Investigators	Jones AL, Carter G, Whyte I et al
Total Funds (\$)	\$30,000
Period	Jan 2010- Dec 2010 (1 year)
Funding Source	NHMRC Partnership Grant (533559)
Title	Reducing impulsive behaviour in repeat violent offenders using a selective serotonin reuptake inhibitor (Zoloft)
% Time and my role	5% - study design, safety committee, implementation, data analysis and write up: AJ = co-CI = \$0
Chief Investigator	Butler T, University of NSW
Total Funds (\$)	\$1,300,000
Period	Jan 2009 - Dec 2012 (4 years)
Funding Source	NHMRC Grant (631098)
Title	H1N1 Australian public's H1N1 knowledge, risk perception, containment measure adoption and willingness to be vaccinated
% Time and my role	10% - study design, questionnaire design, implementation, data analysis and write up: AJ = co-CI(C) = \$0
Top 3 Chief Investigators	Durrheim D, Eastwood K, and Jones AL, University of Newcastle
Total Funds (\$)	\$60,896
Period	July 2009- July 2010 (1 year)
Funding Source	CRC CARE Project Grant (189707)
Title	Adsorbed chemical species on inhalable iron rich particles
% Time and my role	5% - human effects literature evaluation, design and implementation of in vitro toxicology work, interpretation of the in vitro and animal model work on human health and extrapolation to likely public health effects
Top 3 Chief Investigators	Dr Dave Fleming, Dr S Wilkinson, Dr N Rothnie, Curtin University, WA
Total Funds (\$)	\$1,570,602
Period	February 2009 – February 2012 (3 years)
Funding Source	John Hunter Hospital Charitable Foundation Trust
Title	Development of an olfactory stress test for the early identification of Alzheimer's disease – a pilot study
% Time and my role	5% design, analysis of study, overseeing pharmacology aspects: AJ = co-CI
Top 3 Chief Investigators	Schofield PW, Jones AL, Bateman G et al, University of Newcastle
Funds (\$)	\$18,500
Period	2009 (1 year)
Funding Source	National Security Science and Technology Unit - Australian Government Department of the Prime Minister and Cabinet
Title	Addressing challenges of CBRNE terrorism
% Time and my role	15% - design of study, practical implementation of risk communications to enhance community resilience, liaison with core govt departments: AJ = co-CI = \$0
Top 3 Chief Investigators	Prof Beverley Raphael, Margo Barr, Prof Alison Jones, University of Western Sydney
Funds (\$)	\$627,083
Period	2009-2010 (2 years)
Funding Source	ARC – LIEF (LE0989105)
Title	An advanced mass spectrometry facility for applications in proteomic and organic chemistry
Top 3 Primary Investigators	Prof RJ Aitken, A/Prof A McCluskey, Dr MA Baker et al: AJ = co-PI
Funds (\$)	\$495,000 + \$50,000 From UoN
Period	2009
Funding Source	ARC – LIEF (LE0989105)

Funding Source	University of Newcastle Australia
Title	Priority Research Centre for Health Behaviours
% Time and role	5%, leading post-doctoral support and input to overall strategy: AJ = co-CI
Top 4 Investigators	Prof Rob Sanson-Fisher, Prof Afaf Girgis, Prof John Wiggers, Prof AL Jones, University of Newcastle
Funds (\$)	\$79,000
Period	2009 (1 year)
Funding Source	University of Newcastle Australia– NHMRC near miss grant
Title	Genes in serotonin toxicity (GISETTO)
% Time and role	5% design, early PhD supervision, implementation, analysis: AJ = co-CI
Top 3 Chief Investigators	Prof Alison Jones, A/Prof Greg Carter, Prof Ian Whyte et al
Funds (\$)	\$20,000
Period	2009 (1 year)
Funding Source	NSW Department of Health
Title	Provision of high level toxicology advice and toxicology laboratory services review
% Time	“5%” - sole delivery
Chief Investigator	Professor Alison Jones, University of Newcastle
Funds (\$)	\$135,000
Period	2008-2010 (3 years)
Funding Source	Guy's and St Thomas' Charitable Foundation
Title	Guy's Poisons Unit Patient Toxicology Database MORPHEUS
My role	I contributed to development of parameters to be included in database, and to writing the paper and oversight of the project as MTU Director e.g. appointing staff and project planning, and Dr Paul Dargan took over MTU Director role after I migrated to Australia
Investigators	The named investigator on the grant for the database was a toxicology trainee Dr Shaun Greene
Funds (\$)	\$252,720 (based on GBP to AUS \$ currency conversion value of 2.4 in 2006 when I arrived in Australia)
Period	2006-2008 (3 years) Guy's and St Thomas' Trust - Internal funding grants
Funding Source	
Title	Chelation with DMSA; prevalence of undiagnosed lead poisoning.
Investigators	Dr A L Jones, Dr Paul Dargan, Dr B Widdop
Funds (\$)	\$34,523 (based on GBP to AUS \$ currency conversion value of 2.4 in 2006 when I arrived in Australia)
Period	2000-2005 (6 years)
Funding Source	Health Protection Agency; WHO
Title	Small Contracts
Investigator	Dr Alison L Jones
Funds (\$)	\$153,090 (based on GBP to AUD currency conversion value of 2.4 in 2006 when I arrived in Australia)
Period	2001-2005 (5 years)
Funding Source	Archimedes Pharmaceuticals
Title	A toxicological and safety assessment of a fentanyl nasal spray
% of time and role	5% oversight, advisory role and ultimate responsibility role as MTU Director
Investigators	K Heather, N Edwards, R Fitzpatrick, Jones AL
Funds (\$)	\$24,057 (based on GBP to AUD currency conversion value of 2.4 in 2006 when I arrived in Australia)
Period	2006 (1 year)
Funding Source	Engineering and Physical Sciences Research Council, UK
	EPSRC link grant GR/R05154/01
Title	IMI: Activated carbon haemoabsorbents for the removal of middle molecular weight and other toxins from blood
% of time and role	5%. Assisted in design of project, especially the clinical translational importance of the work and choice of carbons. Chaired the steering group, chaired the meetings, helped problem solve as project ensued. AJ= named collaborator on the grant
Investigators	Lead investigator; Prof M Streat, Loughborough University; Co-investigators/collaborators; Dr K Hellgardt; Dr N Hoenich, Dr G Warwick, Dr JA Dale, Mr S Tennison, Mr G Steer, Dr M Street, Dr J Kingswood, Dr Alison Jones
Funds (\$)	\$ 584,067 (based on GBP to AUS \$ currency conversion value of 2.4 in 2006 when I arrived in Australia)
Period	2000-2002 (3 years)
Funding Source	Hospital Filters Lyon and Guy's Hospital – industry funded research
Title	Is haemofiltration effective in removing toxic concentration of therapeutic drugs ?
Investigators	Lead investigator Dr AL Jones; Dr P Dargan, Dr B Widdop.
Funds (\$)	\$ 28978 (\$12150 from Hospital filters) (based on GBP to AUD currency conversion value of 2.4 in 2006 when I arrived in Australia)
Period	1999-2001 (3 years)

Publications

1. Jones AL, Bouchier IAD. A patient with neurosyphilis presenting as chorea. *Scottish Medical Journal* 1993; 38: 82-84.
2. Jones AL, Jarvie DR, McDermid G, Proudfoot AT. Hepatocellular damage after amphetamine intoxication. *Clinical Toxicology* 1994; 32: 435-444.
3. Jones AL, Shearing CS, Plevis JP, Bouchier IAD, Hayes PC. Analysis of serial serum alpha-fetoprotein concentrations in patients in cirrhosis. *Clinical Chemistry and Enzymology Communications* 1994; 6: 237-242.

4. Jones AL, Bangash IH, Bouchier IAD, Hayes PC. Portal and systemic haemodynamic action of N-acetylcysteine in patients with stable cirrhosis. *Gut* 1994; 35: 1290-1293.
5. Jones AL, Hayes PC. Organic nitrates in portal hypertension - a clinical review. *American Journal of Gastroenterology* 1994; 89: 7-14.
6. Jones AL, Bangash IH, Simpson KJ, Finlayson NDC, Hayes PC. Portal and systemic haemodynamic response to acute and chronic administration of low and high dose isosorbide-5-mononitrate in patients with cirrhosis. *Gut* 1995; 36: 104-109.
7. Forrest EH, Jones AL, Dillon J, Walker J, Hayes PC. The effect of nitric oxide synthase inhibition (N⁹-monomethyl-L-arginine) on portal pressure and azygos blood flow in patients with cirrhosis. *Journal of Hepatology* 1995; 23: 254-258.
8. Simpson KJ, Jones AL, Dillon J, Hayes PC. Soluble adhesion molecules and interleukin-2 receptor concentrations in patients with autoimmune chronic hepatitis. *European Journal of Gastroenterology* 1995; 7: 455-460.
9. Hussain I, Hepburn NC, Jones AL, O'Rourke K, Hayes PC. An association of hepatitis C virus infection with *porphyria cutanea tarda* in the Lothian Region of Scotland. *Clinical and Experimental Dermatology* 1996; 21: 283-285.
10. Jones AL, Webb DJ. Selective immunoglobulin A deficiency, hypothyroidism and congenital lymphoedema. *Scottish Medical Journal* 1996; 41(1): 22-23.
11. Jones AL. Chloropicrin (p 10) and Diethylchloride (p 18). In: Handbook of Pesticide Poisoning ("Red Book"). Her Majesty's Stationery Office 1996. [CHAPTER]
12. Jones AL. Hepatotoxicity. In: Fundamental Toxicology for Chemists. Ed: JH Duffs. Royal Society of Chemistry (UK) 1996; 136-144. [CHAPTER]
13. Jones AL, Keighley J, Gold W, Good AM. Eye drops - the hidden poison. *Scottish Medical Journal* 1996; 41: 110-112.
14. Jones AL, Good AM, Proudfoot AT. What's your poison? The development and clinical use of TOXBASE, the primary database of the National Poisons Information Service. *Pharmacy in Practice* 1996; 6(8): 280-282.
15. Jones AL, Hayes PC, Proudfoot AT, Vale JA, Prescott LF. Should methionine be added to every paracetamol tablet? *British Medical Journal* 1997; 315: 301-303.
16. Jones AL, Prescott LF. Unusual complications of paracetamol poisoning. *Quarterly Journal of Medicine* 1997; 90: 161-168.
17. Jones AL, Jarvie DR, Simpson DJ, Hayes PC, Prescott LF. Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. *Alimentary Pharmacology and Therapeutics* 1997; 11: 787-791.
18. Jones AL. "To Good Is Better than to Heal"- Prevention of accidental poisoning and injury of children. *Editorial for International Journal of Clinical Practice* 1997; 51: 268-270.
19. Jones AL, Proudfoot AT. The features and management of poisoning with drugs used to treat Parkinson's disease. *Quarterly Journal of Medicine* 1997; 90: 613-616.
20. Jones AL. Methionine risks not established. *The Pharmaceutical Journal* 1997; 259: 766. [LETTER]
21. Bateson MC, Barton R, Burke D, Cann P, Cox J, Curry G, Ghosh S, Hislop W, Hopwood D, Johnston D, Jones AL, Jowett S, Macklon A, Matthewson K, O'Donoghue J, Palmer K, Reilly T, Rose J, Sivarmakrishnan N, Smith H, Stephen J, Trewby P, Wilson J and Wood R. In: Multiple Choice Questions in gastroenterology and hepatology. Ed: N Bateson. Petroc Press UK 1998. [BOOK]
22. Jones AL, Jarvie DR, Simpson D, Prescott LF. Comparison of assays for measuring plasma paracetamol. Possibility of a calibration error needs evaluation. *British Medical Journal* 1998; 316: 475. [LETTER]
23. Jones AL, Latham T, Shallcross TJ, Simpson KJ. Fulminant hepatic failure due to diclofenac treated successfully by orthotopic liver transplantation. *Transplantation Proceedings* 1998; 30: 192-194.
24. Jones AL, Proudfoot AT. The features and management of poisoning with modern drugs used to treat epilepsy. *Quarterly Journal of Medicine* 1998; 91: 325-332.
25. Stanley A, Robinson I, Jones AL, Forrest EH, Hayes PC. Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis. *Quarterly Journal of Medicine* 1998; 91: 19-25.
26. Jones AL, Lewis S, Doyle D, Agius R, Lawson DH. The Fellows and Members Survey of the Royal College of Physicians of Edinburgh. *Proceedings of the Royal College of Physicians of Edinburgh* 1998; 28: 273-286.
27. Jones AL. Initial management of poisoned patients in the out-of-hospital environment. *Pre-Hospital Immediate Care* (a BMJ publication) 1998; 2: 1-9.
28. Jones AL, Ojar D, Redhead DN, Proudfoot AT. Use of an IVC filter in the management of IVC thrombosis occurring as a complication of acute pancreatitis. *Clinical Radiology* 1998; 53: 462-464.
29. Jones AL. The mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: A critical review. *Clinical Toxicology* 1998; 36: 277-285.
30. Routledge P, Vale JA, Bateman D, Johnston G, Jones AL, Judd A, Thomas S, Volans G, Prescott LF, Proudfoot AT. Paracetamol (acetaminophen) poisoning: No need to change current guidelines to accident departments. *British Medical Journal* 1998; 137: 1609-1610. [LETTER]
31. Jones AL, Lheureux PH. Progrès récents dans le traitement des intoxications au paracétamol. (Recent advances in the management of paracetamol poisoning.) *Réanimation Urgences* 1998; 7: 1-8 La phase précoce. *Réanimation Urgences* 1998; 7: 8-16 La phase tardive.
32. Jones AL, Simpson KJ. Drug abusers and poisoned patients; a potential source of organs for transplantation programmes? *Quarterly Journal of Medicine* 1998; 91: 589-592.
33. Proudfoot AT, Jones AL. Severity scores for poisoned patients; reasons and rationale. In: Intoxications Aigues. Ed: Jaeger A, Vale JA. Elsevier 1999; 78-96. [CHAPTER]
34. Jones AL, Simpson KJ. Mechanisms and management of hepatotoxicity in ecstasy and amphetamine intoxications. *Alimentary Pharmacology and Therapeutics* 1999; 13: 129-133.
35. Jones AL. Drugs of abuse in the intensive care unit setting. In: Yearbook of Intensive Care and Emergency Medicine. Ed: JL Vincent. Springer 1999; 623-633. [CHAPTER]
36. Jones AL, Elton R, Flanagan R. Multiple logistic regression analysis of serum paraquat concentrations as predictive of outcome in 375 cases of paraquat poisoning. *Quarterly Journal of Medicine* 1999; 92: 573-578.
37. Jones AL. Immediate GP strategies in cases of poisoning. *Clinical Pulse* June 1999; 81- 85.
38. Jones AL. Use of an IVC filter in the management of IVC thrombosis. *Clinical Radiology* 1999. 54(3): 198 [LETTER]
39. Jones AL. Paracetamol Poisoning. *Clinical Pulse* May 1999; 73-79
40. Jones AL, Volans G. Recent advances: Management of self-poisoning. *British Medical Journal* 1999; 319: 1414-1417.
41. Jones AL, Volans G. Author's reply - Management of self-poisoning. *British Journal of Medicine* 2000; 320: 712. [LETTER]
42. Jones AL, Proudfoot AT. Chapter 10 Pesticides and other agrochemicals. In: Hunter's Diseases of Occupations. PJ Baxter, PH Adams, T Aw, A Cockcroft, JM Harrington. Arnold London 2000; p 10.1-10.25. [CHAPTER]
43. Jones AL. Recent advances in the management of late paracetamol poisoning. *Emergency Medicine* (Australia) 2000; 12: 14-22.
44. Flanagan RJ, Jones AL. Antidotes 1. Introduction. *Syva Drug Monitor* 2000; 3(7): 52-53.
45. Flanagan RJ, Jones AL. Antidotes 2. Sulphydryl donors (N-acetylcysteine, methionine). *Syva Drug Monitor* 2000; 3: 63-64.
46. Dargan PI, Evans PH, House IM, Jones AL. A case of lead poisoning due to snooker chalk. *Archives of Disease in Childhood* 2000; 83: 519-520
47. Levy S, Jones AL. Improving the debate on cannabis: The effects of cannabis on driving are difficult to evaluate. *British Journal of Medicine* 2000; 320: 1671-1672. [LETTER]
48. Jones AL. Gut Reactions. *Chemist and Druggist* Jul 1 2000.

49. Shin GY, Dargan P, Jones AL. Paracetamol and asthma in adults. *Thorax* 2000; 55: 882 [LETTER]
50. Jones AL, Dargan PI. Churchill's Textbook of Toxicology. Churchill Livingstone, Edinburgh 2001. ISBN 0-443-06476-8 [BOOK]
51. Dargan PI, Ladhani S, Jones AL. Measuring plasma paracetamol concentration in all patients with drug overdose or altered consciousness: Does it change outcome? *Emergency Medicine Journal* 2001; 18: 178-182.
52. Norman E, Dhairiwan R, Dargan PI, Wallace C, Jones AL. Paracetamol poisoning: can it be prevented? *Proceedings of Royal College of Physicians Edinburgh* 2001; 31: 62-65.
53. Flanagan R, Jones AL. Antidotes. A reference manual. Taylor-Francis, London 2001. ISBN 0-748-40965-3 [BOOK]
54. Karim A, Dargan PI, Jones AL. How feasible is it to conform to the European guidelines on administration of activated charcoal within one hour of an overdose? *Emergency Medicine Journal* 2001; 18: 360-362.
55. Prescott LF, Jones AL. Drugs for personal fulfilment in the elderly. *Quarterly Journal of Medicine* 2001; 94: 657-658.
56. Jones AL, Dargan PI. What's New in Toxicology? *Current Paediatrics* 2001; 11: 409-413.
57. Ross JR, Dargan PI, Jones AL, Kostrzewski A. A case of hypomagnesaemia due to malabsorption, unresponsive to oral administration of magnesium glycerophosphate, but responsive to oral magnesium oxide supplementation. *Gut* 2001; 48(6): 857-858.
58. Dargan PI, Jones AL. Reduced packet sizes may decrease paracetamol and salicylate self-poisoning. *Evidence-based Healthcare* 2001; 5: 117-118.
59. Dargan PI, Jones AL. Effects of legislation restricting pack sizes of paracetamol on self-poisoning. *British Medical Journal* 2001; 323: 633.
60. MacLehose R, Pitt G, Will S, Jones AL, Duane L, Flaherty S, Hannant D, Stuttard B, Silverwood A, Snee K, Murray V, Syed Q, House I, Bellis MA. Mercury contamination incident. *Journal of Public Health Medicine* 2001; 23: 18-22.
61. Wallace C, Dargan PI, Jones AL. Paracetamol overdose: an evidence-based flowchart to guide management. *Emergency Medicine Journal* 2002; 19: 202-205. doi:10.1136/emj.19.3.202
62. Dargan PI, Wallace C, Jones AL. An evidence-based flowchart to guide the management of acute salicylate overdose. *Emergency Medicine Journal* 2002; 19: 206-209. doi:10.1136/emj.19.3.206
63. Jones AL. Recent advances in the management of poisoning. *Therapeutic Drug Monitoring* 2002; 24: 150-155. doi:10.1097/00007691-200202000-00023
64. Jones AL, Dargan PI. Advances, challenges and controversies in poisoning. *Emergency Medicine Journal* 2002; 19: 190-191. doi:10.1136/emj.19.3.190
65. Jones AL. Over-the-counter analgesics: a toxicology perspective. *American Journal of Therapeutics* 2002; 9: 245-257.
66. Dargan PI, Jones AL. Acetaminophen poisoning: an update for the intensivist. *Critical Care Medicine* 2002; Apr 6(2) 108-110. doi:10.1186/cc1465
67. Wood DM, Webster E, Martinez D, Dargan PI, Jones AL. Survival after deliberate strychnine self-poisoning, with toxicokinetic data. *Critical Care* 2002; 6: 456-459. doi:10.1186/cc1549
68. Dargan PI, Jones AL. Should a lower treatment line be used when treating paracetamol poisoning in patients with chronic alcoholism? A case against. *Drug Safety* 2002; 25: 625-632. doi:10.2165/00002018-200225090-00002
69. Flanagan RJ, Jones AL. Antidotes 4. Deferoxamine and other iron/aluminium chelators. *Syva Drug Monitor* 2002; 4: 77-78.
70. Flanagan RJ, Jones AL. Antidotes 5. Antidotes to organophosphorus and carbamate anticholinesterases. *Syva Drug Monitor* 2002; 3: 86-88.
71. Flanagan RJ, Jones AL. Antidotes 6. Flumazenil. *Syva Drug Monitor* 2002; 3: 92-93.
72. Jones AL, Karalliedde L. Poisoning. In: Davidson's Principles & Practice of Medicine 19th Edition. Ed: Boon, Colledge, Walker, Hunter. Elsevier/Churchill Livingstone 2002. ISBN:978-0443071119 [CHAPTER]
73. Dargan PI, Jones AL. Paracetamol: balancing risk against benefit. *Quarterly Journal of Medicine* 2002; 95: 831-832. doi:10.1093/qjmed/95.12.831
74. Jones AL. Poisoning and overdose. In: Oxford Handbook of Clinical and Laboratory Investigation 1st Edition. Ed: Provan D, Krentz A. Oxford University Press 2002. ISBN 0-192-63283-3. [CHAPTER]
75. Whelan KR, Jones AL, Dargan PI. Drug misuse should always be considered in young people with impaired consciousness. *British Medical Journal* 2003; 326: 396-397. doi:10.1136/bmj.326.7385.396/b [LETTER]
76. Wood DM, Dargan PI, Jones AL. Poisoned patients as potential organ donors: postal survey of transplant centres and intensive care units. *Critical Care* 2003; 7: 147-154. doi:10.1186/cc1880
77. Dargan PI, Jones AL. Management of paracetamol poisoning. *Trends in Pharmacological Sciences* 2003; 24: 154-157. doi:10.1016/S0165-6147(03)00053-1
78. Greene SL, Dargan PI, O'Connor N, Jones AL, Kerins M. Multiple toxicity from 3,4-methylenedioxymethamphetamine "ecstasy". *American Journal of Emergency Medicine* 2003; 21: 121-124. doi:10.1053/ajem.2003.50028
79. O'Connor N, Dargan PI, Jones AL. Hepatocellular damage from non-steroidal anti-inflammatory drugs. *Quarterly Journal of Medicine* 2003 96(11): 787-791. doi:10.1093/qjmed/hcg138.
80. Kerins M, Dargan PI, Jones AL. Pitfalls in the management of the poisoned patient. Current Medicine. *The Journal of the Royal College of Physicians of Edinburgh* 2003; 33: 90-104.
81. Dargan PI, Giles LJ, Wallace CI, House IM, Thomson AH, Beale RJ, Jones AL. Case report: Severe mercuric sulphate poisoning treated with 2,3-dimercaptopropane-1-sulphonate and haemodiafiltration. *Critical Care* 2003; 7: R1-R6. doi:10.1186/cc1887
82. Flanagan RJ, Jones AL. Antidotes. Immunotherapy. *Syva Drug Monitor* 2003.
83. Flanagan RJ, Jones AL. Antidotes. Antidotes to cyanide. *Syva Drug Monitor* 2003.
84. Jones AL, Flanagan RJ. Benzotropine. In: Medical Toxicology, 3rd edition. Ed: Dart RC. Lippincott, Williams and Wilkins 2004; 166. ISBN:978-0781728454 [CHAPTER]
85. Jones AL, Flanagan RJ. Calcium salts. In: Medical Toxicology, 3rd edition. Ed: Dart RC. Lippincott, Williams and Wilkins 2004; 167-168. ISBN:978-0781728454 [CHAPTER]
86. Jones AL, Flanagan RJ. Digoxin immune fab. In: Medical Toxicology, 3rd edition. Ed: Dart RC. Lippincott, Williams and Wilkins 2004; 182-185. ISBN:978-0781728454 [CHAPTER]
87. Jones AL, Flanagan RJ. Dimercaprol. In: Medical Toxicology, 3rd edition. Ed: Dart RC. Lippincott, Williams and Wilkins 2004; 185-187. ISBN:978-0781728454 [CHAPTER]
88. Jones AL, Flanagan RJ. Dimethyl-p-aminophenol. In: Medical Toxicology, 3rd edition. Ed: Dart RC. Lippincott, Williams and Wilkins 2004; 187-189. ISBN:978-0781728454 [CHAPTER]
89. Jones AL, Flanagan RJ. Dimercaptopropane sulfonic acid (DMPS). In: Medical Toxicology, 3rd edition. Ed: Dart RC. Lippincott, Williams and Wilkins 2004; 193-195. ISBN:978-0781728454 [CHAPTER]
90. Jones AL, Flanagan RJ. Diethylenetriaminepenta-acetate (DTPA). In: Medical Toxicology, 3rd edition. Ed: Dart RC. Lippincott, Williams and Wilkins 2004; 195-196. ISBN:978-0781728454 [CHAPTER]
91. Jones AL, Flanagan RJ. Hyperbaric oxygen. In: Medical Toxicology, 3rd edition. Ed: Dart RC. Lippincott, Williams and Wilkins 2004; 217-220. ISBN:978-0781728454 [CHAPTER]
92. Dart R, Jones AL. N-acetylcysteine. In: Medical Toxicology, 3rd edition. Ed: Dart RC. Lippincott, Williams and Wilkins 2004; 223-228. ISBN:978-0781728454 [CHAPTER]
93. Flanagan RJ, Jones AL. Fab antibody fragments: some applications in clinical toxicology. *Drug Safety* 2004; 27: 1115-1133. doi:10.2165/00002018-200427140-00004
94. Whelan KR, Dargan PI, Jones AL, O'Connor N. Atypical antipsychotics are not recommended for control of agitation in the emergency department. *Emergency Medicine Journal* 2004; 21: 649. [LETTER]

95. Greene SL, Dargan PI, Shin GY, Jones AL. Doctors and nurses estimation of the weight of patients: A preventable source of systematic error. *Clinical Toxicology* 2004; 42: 611-615. doi:10.1081/CLT-200026969
96. Jones AL. Adverse drug reactions to poison antidotes: Part 1. *Adverse Drug Reaction Bulletin* October 2004. ISSN 0044-6394.
97. Jones AL. Adverse drug reactions to poison antidotes: Part 2. *Adverse Drug Reaction Bulletin* December 2004. ISSN 0044-6394.
98. Jones AL. Poisoning and overdose. In: Oxford Handbook of Clinical and Laboratory Investigation 2nd Ed. Ed: Provan D, Krentz. Oxford University Press 2005. Chapter 11: 607-635. ISBN: 0-19263283-3. [CHAPTER]
99. Jones AL. Chapter 14 Complications of chronic alcoholism that affect critical illness. In: Critical Care Toxicology. Ed: Brent, Wallace, Burkhart, Phillips, Donovan. Elsevier Mosby 2005: 163-173. ISBN 0-8151-4387-7. [CHAPTER]
100. Jones AL. Chapter 63 Chloroquine and Quinine. In: Critical Care Toxicology. Ed: Brent, Wallace, Burkhart, Phillips, Donovan. Elsevier Mosby 2005: 673-683. ISBN 0-8151-4387-7. [CHAPTER]
101. Toes M, Jones AL, Prescott LF. Drug interactions with paracetamol. *American Journal of Therapeutics* 2005; 12(1): 56-66.
102. Greene SL, Dargan PI, Jones AL. Acute poisoning: understanding 90% of cases in a nutshell. *Postgraduate Medical Journal* 2005; 81: 204-216. doi:10.1136/pgmj.2004.024794
103. Fowler A, Dargan P, Jones AL. Puzzling hypercalcaemia; sarcoidosis without lung involvement. *Journal of the Royal Society of Medicine* 2005; 98: 60-61. doi:10.1258/jrsm.98.2.60
104. O'Connor, Greene S, Dargan P, Jones AL. Glucagon use in beta-blocker overdose. *Emergency Medicine Journal* 2005; 22: 391. [LETTER]
105. Wood DM, Dargan PI, Jones AL. Measuring plasma salicylate concentrations in all patients with drug overdose or altered consciousness: Is it necessary? *Emergency Medicine Journal* 2005; 22: 401-403. doi:10.1136/emj.2003.010298
106. Wood DM, Wright KD, Jones AL, Dargan PI. Metaraminol (Aramine®) in the management of a significant amlodipine overdose: A case report. *Human and Experimental Toxicology* 2005; 24(7): 377-381. doi:10.1191/0960327105ht5380a
107. Wood D, Alsahaf H, Streete P, Dargan PI, Jones AL. Fatality after deliberate self-ingestion of the pesticide Rotenone: a case report. *Critical Care* 2005; 9: R280-284. doi:10.1186/cc3528
108. Wood D, Thomson AH, Lawes M, Jones AL, Dargan PI. Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child: A case report *Therapeutic Drug Monitoring* 2005; 27(4): 405-408. doi:10.1097/01.fdt.0000166042.97524.8b
109. Jones AL, Dargan PI. Poisoning: Overview and statistics. In: Encyclopedia of Forensic and Legal Medicine. Ed: Payne, Byard, Corey, Henderson. Oxford, U.K Elsevier Academic Press 2005; 447-455. ISBN:978-0125479707 [CHAPTER]
110. Clarke SF, Dargan PI, Jones AL. Naloxone in opioid poisoning: walking the tightrope. *Emergency Medicine Journal* 2005; 22(9): 612-616. doi:10.1136/emj.2003.009613
111. Dargan PI, Colbridge MG, Jones AL. The management of tricyclic antidepressant poisoning: the role of gut decontamination, extracorporeal procedures and FAB antibody fragments. *Toxicological Reviews* 2005; 24(3): 187-194. doi:10.2165/00139709-200524030-00011
112. Wood DM, Greene SL, Dargan PI, Jones AL. Serial Troponin-I measurements are not useful in acute colchicine toxicity. *Emergency Medical Journal* 2005; 22(8) [LETTER]
113. Gawarammana IB, Greene SL, Dargan PI, Jones AL. Australian clinical toxicology investigators collaboration randomized trial of different loading infusion rates of N-acetylcysteine. *Annals of Emergency Medicine* 2006; 47: 124. doi:10.1016/j.annemergmed.2005.07.023 [LETTER]
114. Jones AL, Karalliedde L. Poisoning. In: Davidson's Principles & Practice of Medicine. Ed: Boon, Colledge, Walker, Hunter. Elsevier/Churchill Livingstone 2006; 203-226. ISBN:978-0443100574 [CHAPTER]
115. Jones AL. Chapter 15: Hepatotoxicity. In: Fundamental Toxicology. Ed: JH Duffus, HGJ Worth. Royal Society of Chemistry (UK) 2006; 189-197. ISBN:9780854046140 [CHAPTER]
116. Wood DM, Monaghan J, Streete P, Jones AL, Dargan PI. Fatality after deliberate ingestion of sustained-release ibuprofen: a case report. *Critical Care* 2006; 10(2): R44. doi:10.1186/cc4850
117. Greene SL, Dargan PI, Leman P, Jones AL. Paracetamol availability and recent changes in paracetamol poisoning: is the 1998 legislation limiting availability of paracetamol being followed? *Postgraduate Medical Journal* 2006; 82: 520-523. doi:10.1136/pgmj.2005.042036
118. O'Connor N, Greene S, Dargan P, Wyncoll D, Jones AL. Prolonged clinical effects in modified-release amitriptyline poisoning. *Clinical Toxicology* 2006; 44: 77-80. doi:10.1080/15563650500394910
119. Wood D, Gawarammana I, Greene S, Dargan P, Jones AL. Insufficient evidence that agitation is common in gamma-hydroxybutyrate (GHB) toxicity. *American Journal of Emergency Medicine* 2006; 24: 257. doi:10.1016/j.ajem.2005.09.010 [LETTER]
120. Wood DM, Dargan PI, Jones AL. Mercury: answering some of the current controversies about it. *Journal of the Royal College of Physicians of Edinburgh* 2006; 36: 120-22.
121. Gawarammana IB, Dargan PI, Woodcock S, Sculley M, House IM, Wood DM, Jones AL. Should all patients with unexplained anaemia be screened for chronic lead poisoning? *Human Experimental Toxicology* 2006; 25(11): 645-649. doi:10.1177/0960327106074594
122. Jones AL and Dargan PI. Chapter 11 Hepatic Toxicology. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th Edition. Ed: Shannon M, Borron S, Burns S. Saunders Elsevier 2007; 223-249 ISBN 0-721-60693-8. [CHAPTER]
123. Wood DM, Dargan PI, Button J, Holt DW, Ovaska H, Ramsey J, Jones AL. Collapse, reported seizure and an unexpected pill. *Lancet* 2007; 369: 1490. doi:10.1016/S0140-6736(07)60674-6
124. Wood DM, Hill D, Gunasekera A, Greene SL, Jones AL, Dargan PI. Is cocaine use recognized as a risk factor for acute coronary syndrome by doctors in the UK? *Postgraduate Medical Journal* 2007; 83: 325-328. doi: 10.1136/pgmj.2006.053850
125. Archer JRH, Tizzard Z, Wood D M, Jones AL, Dargan PI. Alcohol Hand Rubs: Hygiene and Hazard. *British Medical Journal* 2007; 335: 1154-1155. doi:10.1136/bmj.39274.583472.AE
126. Wood DM, Greene SL, Jones AL, Dargan PI. Gut decontamination of acutely poisoned patients: what do doctors really know about it? *Emergency Medicine Journal* 2007; 24: 774-775. doi:10.1136/emj.2007.049544
127. Gawarammana I, Coburn J, Greene S, Dargan PI, Jones AL. Severe hypokalaemic alkalosis after Gaviscon ingestion. *Clinical Toxicology* 2007; 45: 176-178. doi:10.1080/15563650600981160
128. Wood DM, Yadhunathanan R, Greene SL, Morgan PE, Gerrie D, Jones AL, Dargan PI. Status epilepticus following intentional overdose of fluvoxamine: A case report with serum fluvoxamine concentration. *Clinical Toxicology* 2007; 1: 1-3. doi:10.1080/15563650701664574
129. Greene S, Gawarammana I, Wood D, Jones AL, Dargan P. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. *Intensive Care Medicine* 2007; 33: 2019-2024. doi: 10.1007/s00134-007-0768-y
130. Jones AL. Chapter 11 Paracetamol poisoning: A young woman who has taken an overdose of paracetamol (acetaminophen). In: Davidson's International Clinical Cases in Medicine. Ed: Strachan, Sharma, Hunter. Churchill-Livingstone Press 2008 and second edition published in 2010. Main edition ISBN 978-0-443-06894-2 International student edition 978-0-443-06893-5 [CHAPTER]
131. Dargan PI, Bishop CR, Chalal CAA, Jones AL, Wood DM. Can medical students identify recreational drugs by name? *Quarterly Journal of Medicine* 2008; 101 (12): 979-982. doi:10.1093/qjmed/hcn110

132. Wood D, Greene SL, Gawarammana IB, Warren-Gash C, Drake N, Jones AL, Dargan PI. Improvement in the management of acutely poisoned patients using an electronic database, prospective audit and targeted educational intervention. *Postgraduate Medical Journal* 2008; 84(997): 603-608. doi:10.1136/pgmj.2007.066043
133. Lidder S, Ovaska H, Archer JR, Greene AL, Jones AL, Dargan PI, Wood DM. Doctors' knowledge of the appropriate use and route of administration of antidotes in the management of recreational drug toxicity. *Emergency Medicine Journal* 2008; 25(12): 820. doi:10.1136/emj.2007.054890
134. Ovaska H, Wood DM, House I, Dargan PI, Jones AL, Murray S. Severe iatrogenic bismuth poisoning with bismuth iodoform paraffin paste treated with DMPS chelation. *Clinical Toxicology* 2008; 46(9): 855-857. doi:10.1080/15563650801953182
135. Jones AL, Dargan PI. Toxicologie D'Urgence. Handbook on clinical toxicology (in French). Elsevier 2008. ISBN 978-2-84299-566-9 [BOOK]
136. Jones AL. Chapter 4 Poisoning. In: Davidson's Essentials of Medicine. Ed: Innes AJ. Churchill Livingstone, Elsevier, Edinburgh 2009; 33-47. Main edition ISBN 9780-702-03001-7; International edition ISBN 9780-702-03000-0. [CHAPTER]
137. Clarke SFJ, Torok R, Dargan PI, Jones AL. Chapter 27 Emergency Room use of opioid antagonists in drug intoxication and overdose. In: Opiate receptors and antagonists: from bench to clinic. Ed. Negus S, Bilsky E. Dean RL. Humana Press 2009; 511-539. ISBN 978-1-58829-881-2. [CHAPTER]
138. Wilson A, Bonevski B, Jones A, Henry D. Media reporting of health interventions: signs of improvement, but major problems persist. *PLOS One* 2009 4(3): 1-5 e4831. doi: 10.1371/journal.pone.0004831
139. Jones AL. Chapter 13 Toxicology. In: Essential Clinical Medicine: Symptoms, Diagnosis, Management. Ed: T Gibson, J Rees. Cambridge, UK: Cambridge University Press 2009; 383-399. ISBN: 9780521835732 [CHAPTER]
140. Heyworth JS, Reynolds C and Jones AL. A Tale of Two Towns- Observations on risk perception of environmental lead exposure in Port Pirie and Esperance. *Australia Environmental Health* 2009; 9: 60-73. ISSN: 1444-5212
141. Lai W, Lane T, Jones AL. Sources and Coverage of Medical News on Front Pages of US Newspapers. *PLOS One* 2009, 4(9): e6856. doi:10.1371/journal.pone.0006856
142. Athuraliya TN, Jones AL. Prolonged N-acetylcysteine therapy in late Acetaminophen (APAP) poisoning associated with acute liver failure – a need to be more cautious? *Critical Care* 2009; 13: 144. doi:10.1186/cc7800
143. Cooper J, Jones AL. Neuroleptic malignant syndrome or a statin drug reaction? A case report. *Clinical Neuropharmacology* 2009; 32(6): 348-349. doi:10.1097/WNF.0b013e3181acc92d
144. Jones AL. Emerging aspects of lead poisoning in childhood. *Emerging Health Threats Review* 2009; 2: e3. doi: 10.3134/ehj.09.003
145. Jones AL, Kable S. Amphetamine overdose. British Medical Journal Point of Care guidelines– online. First edition 2009 – revised 2010, 2011, 2012 and 2013.
146. Jones AL. Poisoning and overdose. In: Oxford Handbook of Clinical and Laboratory Investigation 3rd Edition. Ed: Provan D. Oxford University Press 2010. ISBN 978-0-19-923371-7. [CHAPTER]
147. Ovaska H, Ludman A, Wood DM, Spencer E, Jones AL, Dargan PI. Propafenone poisoning – a case report with plasma propafenone concentrations. *Journal of Medical Toxicology* 2010; 6: 37-40. doi 10.1007/s13181-010-0037-2
148. Eastwood K, Durrheim DN, Jones AL, Butler M. Acceptance of pandemic (H1N1) 2009 influenza vaccination by the Australian Public. *Medical Journal of Australia* 2010;192(1): 33-36.
149. Jones AL. Legal “highs” available through the Internet – implications and solutions? *Quarterly Journal of Medicine* 2010; 103: 535-536. doi:10.1093/qjmed/hcq066
150. Stevens G, Agho K, Raphael B, Taylor M, Jones AL, Smith GT, Nelson J. Determinants of Paramedic Response Readiness for CBRNE threats. Biosecurity and Bioterrorism: *Biodefense Strategy, Practice and Science* 2010; 8; 2: 193-202. doi:10.1089/bsp.2009.0061
151. Wilson A, Robertson J, McElduff P, Jones AL, Henry D. Does it matter who writes medical stories ? *PLOS Medicine* Sept 2010, 7(9); e1000323. doi:10.1371/journal.pmed.1000323
152. Rahman R, Faiz MA, Selim S, Rahman B, Basher A, Jones AL, D'Este C, Hossein M, Islam Z, Ahmed H, Milton AH. Annual incidence of snake bite in rural Bangladesh. *PLOS Neglected Tropical Disease* 2010; 4(10). e860. Doi:10.1371/journal.pntd.0000860
153. Eastwood K, Durrheim D, Butler M, Jones AL. Responses to pandemic (H1N1) 2009, Australia. *Emerging Infectious Diseases* 2010; 16(8): 1211-1216. doi:10.3201/eid1608.100132
154. Wilson A, Bonevski B, Henry D, Jones AL. Deconstructing cancer. What makes a good quality news story? *Medical Journal of Australia* 2010, Dec 6-20;193(11-12):702-6.
155. McCarthy L, Jones AL, Yeomans N, Bambrick H, Pacey F, Ramanathan J, Wills T. Engaging for health: medicine in context as a case study in engaged teaching and learning for students in medicine. *Australasian Journal of University Community Engagement* 2010; 5(2): 67-87. ISSN: 1833-4482
156. Dassanayake T, Michie P, Carter G, Jones AL. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review of epidemiological and experimental evidence. *Drug Safety* Feb 2011;34(2):125-156. doi:10.2165/11539050-000000002011
157. Stevens G, Agho K, Taylor M, Jones AL, Jacobs J, Barr M, Raphael B. Alert but less alarmed: a pooled analysis of terrorism threat perception in Australia. *BMC Public Health* 2011; 11: 797. doi:10.1186/1471-2458-11-797
158. Quilty S, Harris LM, Kewley J, Jones AL, Pearce R, James R, McGain F. A Pandora's box: sustainable pharmaceutical supply. *Medical Journal of Australia* 2011; 195(9): 1-3. doi:10.5694/mja11.11150
159. Taylor MP, Schniering CA, Lanphear BP, Jones AL. Lessons learned on lead poisoning in children. One-hundred years on from Turner's declaration. *Journal of Pediatrics and Child Health* 2011; 47: 849-856. doi 10.1111/j.1440-1754.2010.01777.x
160. Athuraliya NT, Abeysekera TD, Amerasinghe PH, Kumarasiri R, Budera P, Karunaratne U, Milton AH, Jones AL. Uncertain etiologies of proteinuric-chronic kidney disease in rural Sri Lanka. *Kidney International* 2011; 80: 1212-1221. doi:10.1038/ki.2011.258
161. Jones AL. Paracetamol (acetaminophen) overdose. In: Davidson's 100 clinical cases 2nd Edition Chapter 16, Elsevier 2012. ISBN: 978-0-7020-4459-5 [CHAPTER]
162. Athuraliya N, Abeysekera T, Amerasinghe PH, Kumarasiri R, Bandara P, Karunaratne U, Milton AH and Jones AL. The author's reply to On uncertain etiologies of proteinuric-chronic kidney disease in rural Sri Lanka. *Kidney International* 2012;81; 1277. doi:210.1038/ki.2012.52 [LETTER]
163. Stevens G, Agho K, Taylor M, Jones AL, Jacobs J, Barr M, Raphael B. Perceived coping and concern predict terrorism preparedness in Australia. *BMC Public Health* 2012; 12: 1117. doi:10.1186/1471-2458-12-1117
164. Schofield P, Ebrahimi H, Jones AL, Bateman GA, Murray SR. An olfactory “stress test” may detect preclinical Alzheimer's disease. *BMC Neurology* 2012; May 2: 12-24. doi:10.1186/1471-2377-12-24
165. Dassanayake TL, Jones AL, Michie PT, Carter GL, McElduff P, Stokes BJ, Whyte IM. Risk of road traffic accidents in patients discharged following treatment for psychotropic drug overdose: a self-controlled case series in Australia. *CNS Drugs* 2012; 26: 268-276. doi:10.2165/11599790-000000000-00000
166. Dassanayake TL, Michie PT, Jones A, Mallard T, Whyte I. Cognitive impairment in patients clinically recovered from central nervous system depressant drug overdose. *Journal of Clinical Psychopharmacology* 2012; 32: 503-510. doi:10.1097/JCP.0b013e31825d6ddb

167. Dassanayake TL, Michie PT, Jones AL, Mallard T, Whyte IM, Carter GL. Cognitive skills underlying driving in patients discharged following self-poisoning with CNS depressant drugs. *Traffic Injury Prevention* 2012; 13:450-457. doi:10.1080/15389588.2012.671983
168. Stevens GJ, Dunsmore JC, Agho KE, Taylor ME, Jones AL, van Ritten JJ, Raphael B. Long-term health and wellbeing of people affected by the 2002 Bali bombing. *Medical Journal of Australia* 2013; 198: 273-277. doi:10.5694/mja12.11480
169. Stevens GJ, Dunsmore JC, Agho KE, Jones AL, Raphael B. Coping support factors among Australians affected by terrorism: 2002 Bali bombing survivors speak. *Medical Journal of Australia* 2013; 199: 772-775. doi:10.5694/mja13.10540
170. Cooper J, Newby D, Whyte I, Carter G, Jones AL, Isbister G. Serotonin toxicity from antidepressant overdose and its association with the T102C polymorphism of the 5-HT_{2A} receptor. *The Pharmacogenomics Journal* 2014; 14: 390-394. doi:10.1038/tj.2013.47
171. Patterson B, Butler M, Eastwood K, Cashman P, Jones AL, Durrheim D. Cross-sectional survey of human-bat interaction in Australia: public health implications. *BMC Public Health* 2014; 14: 58. doi:10.1186/1471-2458-14-58
172. Sellors K, Jones AL, Chan B. Death due to intravenous use of alpha-pyrrolidinopentiophenone (α -PVP). *Medical Journal of Australia* 2014; 201: 601-603. doi:10.5694/mja13.00203
173. Oxley SP, Dassanayake TL, Carter GL, Whyte I, Jones AL, Cooper G, Michie P. Neurocognitive recovery after hospital-treated deliberate self-poisoning with central nervous system depressant drugs: a longitudinal cohort study. *Journal of Clinical Psychopharmacology* 2015; 35(6): 672-680. doi:10.1097/JCP.0000000000000417
174. O'Hara K, Wright I, Schneider JJ, Jones AL, Martin JH. Pharmacokinetics of neonatal prescribing: evidence base, paradigms and the future. *British Journal of Clinical Pharmacology* 2015; 80(6): 1281-1288 doi:10.1111/bcp.12741
175. Doogue M and Jones AL. Chapter 4 Clinical Pharmacology and Toxicology. In: Essentials of Internal Medicine Ed: NJ Talley, B Frankum, D Currow. Australia: Elsevier 2015: 27-55. ISBN: 9780729540810 [CHAPTER]
176. Burton K, Whitelaw J, Jones AL, Davies B. Efficiency of respirator filter media against diesel particulate matter: a comparison study using two diesel particulate sources. *Annals of Occupational Hygiene* 2016; 1-9. doi:10.1093/annhyg/mew026
177. Townsend M, Riepsamen A, Georgiou C, Flood VM, Caputi P, Wright IM, David J, Jones AL, Larkin TA, Williamson MJ, Grenyer BFS. Longitudinal intergenerational birth cohort designs: a systematic review of Australian and New Zealand studies. *PLoS One* 2016; 11(3); e0150491. doi:10.1371/journal.pone.0150491
178. Durrheim D, Jones AL. Public health and the necessary limits of academic freedom? *Vaccine* 2016; 34: 2467-2468. doi:10.1016/j.vaccine.2016.03.082
179. Jones AL. Management of opioid poisoning. In: Oxford Textbook of Critical Care 2nd Edition. Ed: A Webb, D Angus, S Finfer, L Gattinoni and M Singer. Oxford University Press 2016. Chapter 319: 1523-1525. ISBN: 9780199600830 [CHAPTER]
180. Jones AL. Chloroquine and Quinine poisoning. In: Critical Care Toxicology 2nd Edition. Ed: J Brent, KK Burkhardt, PI Dragan, B Hatten, B Megarbane and R Palmer. Switzerland: Springer International Publishing 2017: 1271-1286. ISBN: 978-3-319-17899-8 [CHAPTER]
181. Jones AL. Complications of chronic alcoholism that affect critical illness. In: Critical Care Toxicology 2nd Edition. Ed: J Brent, KK Burkhardt, PI Dragan, B Hatten, B Megarbane and R Palmer. Switzerland: Springer International Publishing 2017: 249-266. ISBN: 978-3-319-17899-8 [CHAPTER]
182. Morgan J, Jones AL. The role of naloxone in the opioid crisis. *Toxicology Communications* 2018; 2(1); 15-18. doi:10.1080/24734306.2018.1458464
183. Breitbarth AK, Morgan J, Alison AL. E-cigarettes – An unintended illicit drug delivery system. *Drug Alcohol Depend.* 2018; 192: 98-111. doi: 10.1016/j.drugalcdep.2018.07.031
184. Hu M, Zheng P, Xie Y, Boz Z, Yu Y, Tang R, Jones A, Zheng K, Huang X-F. Propionate protects haloperidol-induced neurite lesions mediated by neuropeptide Y. *Front Neurosci.* 2018; 12: 743. doi: 10.3389/fnins.2018.00743
185. Jones AL. Poisoning and overdose. In: Oxford Handbook of Clinical and Laboratory Investigation 4th Edition. Ed: Provan D. Oxford University Press 2018. ISBN 978-0198766537. [CHAPTER]
186. Chen J, Chen H, Feng J, Zhang L, Li J, Li R, Wang S, Wilson I, Jones A, Tan Y, Yang F, Huang X-F. Association between hyperuricemia and metabolic syndrome in patients suffering from bipolar disorder. *BMC Psychiatry* 2018; 18: 390. doi: 10.1186/s12888-018-1952-z
187. Solowij N, Broyd S, Greenwood L, van Hell H, Martellozzo D, Rueb K, Todd J, Liu Z, Galettis P, Martin J, Murray R, Jones A, Michie PT, Croft R. A randomised controlled trial of Δ^9 -tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. *Eur Arch Psychiatry Clin Neurosci* 2019; 269: 17-35. doi: 10.1007/s00406-019-00978-2
188. Morgan J, Breitbarth AK, Jones AL. Risk versus regulation: an update on the state of e-cigarette control in Australia. *Intern Med J* 2019; 49: 110-113. doi:10.1111/imj.14176
189. Townsend ML, Kelly MA, Pickard JA, Larkin TA, Flood VM, Caputi P, Wright IM, Jones A, Grenyer BFS. Illawarra born cross-generational health study: feasibility of a multi-generational birth cohort study. *Pilot Feasibility Stud* 2019; 5:32. doi:10.1186/s40814-019-0418-5
190. Stevens GJ, Hammond TE, Brownhill S, Anand M, de la Riva A, Hawkins J, Chapman T, Baldacchino R, Micallef J, Andepalli J, Kotak A, Gunja N, Page A, Gould G, Ryan CJ, Whyte IM, Carter GL, Jones A. SMS SOS: a randomized controlled trial to reduce self-harm and suicide attempts using SMS text messaging. *BMC Psychiatry* 2019; 19:117 doi: 10.1186/s12888-019-2104-9
191. O'Hara K, Schneider JJ, Jones AL, Wright IMR, Martin JH, Galettis P. Development of an UHPLC-MS/MS method for remifentanyl quantification in a small plasma volume. *J Liq Chromatogr Relat Technol* 2019. doi: 10.1080/10826076.2019.1631178
192. Scrimgeour S, Sanburg ALC, Jones A, Narkowicz C, Schneider JJ, McLachlan AJ. Pharmaceutical quality of antibiotics in small island nations in the Western Pacific region: a pilot study. *J Pharm Pract Res* 2019; 49: 426-432. doi: 10.1002/jppr.1540
193. Chen J-X, Zhang L-G, Liu K-Z, Chen H-M, Zhou S-J, Wang N, Tan Y-L, Wang S-L, Jones A, Yang F-D, Huang X-F. Patients with drug-naïve bipolar disorder in remission after 8 weeks of treatment had decreased serum uric acid concentrations. *Front Psychiatry* 2019; 10: 767. doi: 10.3389/fpsy.2019.00767
194. Morgan J, Jones A. Pill-testing as a harm reduction strategy: time to have the conversation. *Med J Aust* 2019; 211(10):447-448.e1. doi: 10.5691/mja2.50385
195. Chen X, Yu Y, Zheng P, Jin T, He M, Zheng M, Song X, Jones A, Huang X-F. Olanzapine increases AMPK-NPY orexigenic signaling by disrupting H1R-GHSR1a interaction in the hypothalamic neurons of mice. *Psychoneuroendocrinol* 2020 doi:https://doi.org/10.1016/j.psyneuen.2020.104594
196. Morgan J, Bell R, Jones A. Endogenous doesn't always mean innocuous: a scoping review of iron toxicity by inhalation. *J Toxicol Environ Health Part B* 2020 doi: 10.1080/10937404.2020.1731896
197. Morgan J, Jones AL. Considerations when estimating fluid consumption volumes in electronic cigarettes. *JAMA Internal Med* 2020; 180(3):468. doi:10.1001/jamainternmed.2019.6633
198. Jody Morgan, Alison Jones, Celine Kelso, Nicotine in electronic cigarette fluid: importation pathways to unequal harm. *Internal Med J* First published: 18 July 2021 https://doi.org/10.1111/imj.15412
199. Butler T, Schofield PW, Knight L et al, Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial, *BMJ Open* 2021; 11: e044656. Doi:10.1136/bmjopen-2020-044656

200. Meyer B et al. The effect of omega-3 long chain polyunsaturated fatty acids on aggressive behaviour in adult male prisoners: a structured study protocol for a multi-centre, double-blind, randomised placebo-controlled trial and translation into policy and practice. *Trials* (2021) 22:318. <https://doi.org/10.1186/s13063-021-05252-2>

Presentations to Learned Societies/Published Abstracts

1. The effect of N-acetylcysteine on cardiac output and tissue oxygen utilisation in cirrhosis.
Jones AL, Hayes PC.
British Society of Gastroenterology Spring Meeting 1993.
Gut 1993; 34(S43); T167.
2. Soluble adhesion molecules in immune liver disease.
Simpson KJ, Jones AL, Hayes PC.
British Society of Gastroenterology Spring Meeting 1993.
Gut 1993; 34(S22); T83.
3. Soluble adhesion molecules in autoimmune chronic active hepatitis.
Simpson KJ, Jones AL, Howie AF, Bouchier IAD, Hayes PC.
Scottish Society For Experimental Medicine May 1993.
Scottish Medical Journal 1994; 39: 58.
4. The acute and chronic action of 10 mg and 40 mg isosorbide-5-mononitrate on azygos vein blood flow and portal pressure in patients with alcoholic cirrhosis.
Jones AL, Finlayson NDC, Hayes PC.
British Society of Gastroenterology Annual Meeting September 1993.
Gut 1993; 34(S20); T80.
5. Ursodeoxycholic acid in the treatment of alcoholic liver disease.
Plevris JP, Jones AL, Bouchier IAD, Hayes PC.
British Society of Gastroenterology Annual Meeting September 1993.
Gut 1993; 34(S7); W26.
6. Soluble adhesion molecules in patients following liver transplantation.
Simpson KJ, Jones AL, Bouchier IAD, Finlayson NDC, Hayes PC.
Hepatology 1993; 18: 343A.
7. The effect of N9-monomethyl-L-arginine (L-NMMA) on portal pressure gradient and azygos blood flow amongst patients with cirrhosis.
Forrest E, Jones AL, Dillon J, Hayes PC.
British Society of Gastroenterology Spring Meeting 1994.
Gut 1994; 35(S20); T80.
8. Soluble adhesion molecules and cytokines in autoimmune chronic active hepatitis (AICAH).
Simpson KJ, Jones AL, Dillon JF, Bouchier IAD, Hayes PC.
British Society of Gastroenterology Spring Meeting 1994.
Gut 1994; 35(S10); W39.
9. Pharmacokinetics of N-acetylcysteine are altered in chronic liver disease.
Jones AL, Jarvie DR, Prescott LF, Proudfoot AT, Hayes PC.
British Society of Gastroenterology 1994.
Gut 1994;35(S10): W41.
10. Angiodysplasia, aortic stenosis and the role of von Willebrand factors.
Jones AL, Ludlam CJ, Boon NA.
Presented to the Medical Research Society April 1994,
Published in *Clinical Science* 1994.
11. N-acetylcysteine is a potent peripheral vasodilator.
Jones AL, Haynes W, MacGilchrist AJ, Webb DJ, Hayes PC.
British Society of Gastroenterology 1994.
Gut 1994;35(S10): W40.
12. Pharmacokinetics of N-acetylcysteine are altered in chronic liver disease.
Jones AL, Jarvie DR, Prescott LF and Proudfoot AT.
XVIIth International Congress of the European Association of Poisons Control Centres and Clinical Toxicologists (EAPCCT), Vienna, April 1994.
13. The association of Hepatitis C viral infection (HCV) with porphyria cutanea tarda (PCT) in the Lothian region of Scotland.
Hussain I, Hepburn NC, Jones AL, O'Rourke K, Hayes PC.
British Society of Gastroenterology 1994.
Gut 1994; 35(S10): T158.
14. Should methionine be added to every paracetamol tablet?
12th Course on Advances in Clinical Toxicology.
February 1996, Birmingham, UK.
15. The haemodynamic actions of N-acetylcysteine and their importance in the management of patients with paracetamol poisoning. Jones AL.
XVIIth International Congress of the European Association of Poisons Control Centres and Clinical Toxicologists (EAPCCT)
Research Prize Lecture, Marseilles 1996.
16. Should methionine be added to every paracetamol tablet?
Jones AL.
XVIIth International Congress of the European Association of Poisons Control Centres and Clinical Toxicologists (EAPCCT), Marseilles 1996.
17. Mapping telephone calls to geographical source in the Scottish Poisons Information Bureau.
Jones AL, Proudfoot AT.
XVIIth International Congress of the European Association of Poisons Control Centres and Clinical Toxicologists (EAPCCT), Marseilles 1996.
18. A comparative study of analytical methods for assay of plasma paracetamol concentration in patients presenting late with paracetamol poisoning.
Jones AL, Jarvie DR, Simpson D, Prescott LF, Proudfoot AT.
XVIIth International Congress of the European Association of Poisons Control Centres and Clinical Toxicologists (EAPCCT), Marseilles 1996.

19. Drugs of abuse in the ITU setting.
Jones AL.
Guest Lecture, Scottish Intensive Care Society, Stirling - 31st January 1997.
20. The mechanism of action and value of N-acetylcysteine in paracetamol poisoning.
Jones AL.
Keynote Lecture at the XVIIIth International Congress of EAPCCT, Oslo 1997.
21. Doctors attitudes towards paracetamol-poisoned patients and referral for liver transplantation.
Jones AL, Gordon LD, Masterton G, Hayes PC, Proudfoot AT.
XVIIIth International Congress of EAPCCT, Oslo 1997.
22. Pro-inflammatory chemokine concentrations are elevated in patients with late paracetamol poisoning.
Jones AL, Simpson KJ, Lukacs N, Strieter R, Kunkel S.
XVIIIth International Congress of EAPCCT, Oslo 1997.
23. Evaluation of treatment in paracetamol poisoning.
Laing W, Jones AL, Proudfoot AT.
XVIIIth International Congress of EAPCCT, Oslo 1997.
24. Attitudes to paracetamol-poisoned patients and their referral for liver transplantation.
Jones AL, Gordon LD, Masterton G, Hayes PC, Proudfoot AT.
Meeting of the Academies of Medicine of Malaysia and Singapore at the Royal College of Physicians Of Edinburgh, September 1997.
25. Enhancement of Elimination.
Jones AL.
WHO / IPCS National Workshop on Poisons Control Programme for Pakistan, Islamabad, November 1997.
26. Drugs of abuse.
Jones AL.
WHO / IPCS National Workshop on Poisons Control Programme for Pakistan, Islamabad, November 1997.
27. Analgesic drug overdose.
Jones AL.
WHO / IPCS National Workshop on Poisons Control Programme for Pakistan, Islamabad, November 1997.
28. Carbon monoxide.
Jones AL.
WHO / IPCS National Workshop on Poisons Control Programme for Pakistan, Islamabad, November 1997.
29. Household chemicals and corrosives.
Jones AL.
WHO / IPCS National Workshop on Poisons Control Programme for Pakistan, Islamabad, November 1997.
30. Methanol and ethylene glycol poisoning.
Jones AL.
WHO / IPCS National Workshop on Poisons Control Programme for Pakistan, Islamabad, November 1997.
31. Principles of care of the poisoned patient.
Jones AL.
Rawalpindi Medical College, Rawalpindi, November 1997.
32. Myths and misconceptions in clinical toxicology.
Jones AL.
Rawalpindi Medical College, Rawalpindi, November 1997.
33. Deaths from paracetamol poisoning in Scotland; Impact of the Scottish Liver Transplant Unit.
Blair CS, Simpson KJ, Jones AL, Squires T, Masterton G, Gormon D, Busuttill A, Hayes PC.
British Society of Gastroenterology meeting 1998.
Gut 1998; 42: suppl 1: A29
34. Mechanisms and management of hepatotoxicity from amphetamines and ecstasy.
Jones AL.
Keynote Lecture at the XVIIIth International Congress of EAPCCT, Zurich 1998.
35. High plasma paracetamol concentrations are not predictive of poor outcome in those who receive N-acetylcysteine treatment.
Good AM, Jones AL.
XVIIIth International Congress of EAPCCT, Zurich 1998.
36. Fulminant hepatic failure as a result of administration of diclofenac treated successfully by orthotopic liver transplantation.
Jones AL, Latham T, Shallcross T, Simpson KJ.
XVIIIth International Congress of EAPCCT, Zurich 1998.
37. The origin of errors in dosage: acetylcysteine as a paradigm.
Ferner RE, Hutchings A, Anton C, Almond S, Jones AL, Routledge PA.
British Pharmacology Society Meeting, Brighton, 1998.
38. Ecstasy or agony?
Highlands Medical Symposium, Fort William,
Royal College of Physicians of Edinburgh, 1999.
39. Care of patients poisoned with drugs of abuse in the Intensive Care.
Jones AL,
State-of-the art lecture.
World Congress of Intensive Care, Brussels, 1999.
40. Optimum management of late paracetamol poisoning.
Jones AL,
State-of-the art lecture.
World Congress of Intensive Care, Brussels, 1999.
41. Drug-induced liver disease.
Jones AL,

- State-of-the art lecture.
World Congress of Intensive Care, Brussels, 1999.
42. Assessing the severity of acute poisoning.
Jones AL,
State-of-the art lecture.
World Congress of Intensive Care, Brussels, 1999.
 43. Is the use of the NPIS (London) centre by NHS Direct line appropriate?
Campbell A, Jones A, Edwards, N, Volans G,
EAPCCT meeting, Dublin 1999.
 44. Risk assessment and communication in the event of a drug withdrawal, the role of a poisons information center.
Dargan PI, Jones AL.
NAACT Meeting, La Jolla, USA . ClinTox 1999; 37: 600.
 45. A case of severe mercuric sulfate ingestion treated with 2,3-dimercaptopropane-1-sulphonate (DMPS) and hi-flow hemodiafiltration.
Dargan PI, Jones AL.
NAACT Meeting, La Jolla, USA. ClinTox 1999; 37: 622.
 46. The treatment of lead poisoning – clinical experience of the National Poisons Information Service (London) 1997-1998.
Dargan PI, Jones AL.
NAACT Meeting, La Jolla, USA. ClinTox 1999; 37: 626.
 47. Lessons from a unique “carbamate” incident.
Jones AL, Murray VSG.
NAACT Meeting, La Jolla, ClinTox 1999; 37: 663.
 48. Use of multiple logistic regression analysis of plasma paraquat concentrations to predict outcome.
Jones AL, Dargan PI, Flanagan R.
NAACT Meeting, La Jolla, ClinTox 1999; 37: 600.
 49. WHO/IPCS lecturer in Katmandhu Nepal on pesticide poisoning, poisoning with household products, snakes, heavy metals, analgesics, antidepressants, chemicals etc. November 1999.
 50. Pharmacology of analgesics
Analgesics Symposium,
Beirut, 2000.
 51. Toxicology of analgesics
Jones AL,
Analgesics Symposium,
Beirut, 2000.
 52. Gastrointestinal effects of NSAIDs.
Jones AL,
CEE Analgesics Meeting, Warsaw 2000.
 53. Cellular barriers to absorption; how this affects clinical toxicity.
Jones AL,
Keynote lecture at the BTS meeting, York, 2000.
 54. Invasive haemodynamic monitoring and the management of shock – a step too far for the poisoned patient.
Jones AL,
Keynote Lecture; XXth International Congress of EAPCCT, Amsterdam 2000.
Clinical toxicology 2000: 38: 164-165.
 55. Measuring plasma paracetamol concentrations in all patients with drug overdose or altered consciousness: does it alter outcome?
Dargan PI, Ladhani S, Jones AL.
XXth International Congress of EAPCCT, Amsterdam 2000.
Clinical toxicology 2000: 38: 204.
 56. Methadone overdoses in the UK: patterns and prevention.
Jones AL, Dargan PI, Gordon LD
XXth International Congress of EAPCCT, Amsterdam 2000.
Clinical toxicology 2000: 38: 230-231.
 57. Snooker chalk – an unusual case of lead poisoning in a child
Dargan PI, Evans PH, Jones AL
XXth International Congress of EAPCCT, Amsterdam 2000.
Clinical toxicology 2000: 38: 251.
 58. A case of serious bismuth poisoning treated with early DMPS without sequelae of renal failure
Bogle RG, Shanmugalingham S, Ross S, Oyenubi A, House I, Jones AL,
Volans G,
XXth International Congress of EAPCCT, Amsterdam 2000.
Clinical toxicology 2000: 38: 253.
 59. What’s new in paracetamol poisoning ?
Jones AL,
Keynote Lecture at the British Pharmacology Society Meeting, June 2000
 60. Paediatric toxicology emergencies.
Jones AL,
Keynote lecture; Royal College of Physicians of Edinburgh Symposium , September 2000
 61. Toxic dilemmas.
Jones AL,
Keynote lecture; Royal College of Physicians of Edinburgh Symposium , September 2000
 62. Lectures on paracetamol poisoning and poisoning with newer drugs of abuse.
Jones AL, All Italian Toxicology Course. Milan, 2000.
 63. Salicylates, methanol and ethylene glycol poisoning. Renal Physiology for the

- Clinicians Meeting, Royal Free Hospital, London February 2001.
64. Management of poisoning. Jones AL, Acute Medical Emergencies Course, Royal College of Physician London, March 2001.
 65. What's new in poisoning ? Jones AL. London Intensive Care Group, April 2001.
 66. Cyanide poisoning managed with hydroxocobalamin in the UK. Campbell A, Jones AL. XXIth International Congress of EAPCCT, Barcelona 2001. Clinical Toxicology 2001:
 67. Is QRS prolongation on the ECG predictive of cardiotoxicity in children ? Colbridge M, Dargan PI, Britto J, Jones AL. XXIth International Congress of EAPCCT, Barcelona 2001. Clinical Toxicology 2001.
 68. Development of a New Toxicology Service. Danish Clinical Pharmacology and Toxicology Society Meeting, Copenhagen, 2001
 69. New Developments in Toxicology. Intensive Care Society Annual Meeting, Bournemouth June 2001.
 70. WHO Training Course in Toxicology for Russia, Moscow. August 2001. Teaching on hepatotoxicity, symptomatic and supportive measures, clinical services and drugs of abuse.
 71. Recent advances in the management of poisoning. Jones AL, 7TH International Congress on TDM and Clinical Toxicology, Washington September 2001.
 72. NAACT –9 abstracts – Montreal September 2001.
 73. RCPL Regional update November 2001; What's New in Toxicology ?
 74. South Of Devon Intensive Care Society; New developments in poisoned patients in the intensive care. 2001
 75. Analgesics Symposium. Amsterdam. Key note lecture on toxicoepidemiology of analgesic poisoning. 2002
 76. Belfast ITU Society – key note lecture “What's New in poisoning ?” 2002
 77. HPA Keynote lecture on mercury toxicity. HPA Annual congress, Cardiff 2004
 78. North west Update RCPL 2004 Drug overdose.
 79. RCPE Updates in acute medicine. Aberdeen 2005.
 80. “What can we really do in managing chemical incidents?”. Life Support 2005, Birmingham, UK
 81. Keynote lecture on N-acetylcysteine; hepatoprotection and nephroprotection. Eur Soc of Emerg Med, Leuven 2005
 82. Recent Advances in Medicine Symposium. Royal College of Physicians, Preston, 2005
 83. Updates in Acute Medicine Symposium. Royal College of Physicians of Edinburgh, 2005
 84. Keynote lecture on hepatotoxicity of herbal preparations. EAPCCT meeting, Prague, 2006
 85. Lecture on toxicology to Intensive Care Society, Kilkenny, Ireland, 2006
 86. Death following ibuprofen overdose: a case report. Monaghan J, Wood DM, Streete P, Dargan PI, Jones AL. Poster presentation: EAPCCT Prague 2006.
 87. Hepatotoxicity of Plants. Jones AL, Dargan PI. Clinical Toxicology 2006;44:463-4. Keynote Lecture (Jones AL), EAPCCT Prague 2006.
 88. Survey of antidote holdings in A&E departments in UK. Dev S, Dines AM, Collignon U, Jones AL, Dargan PI. Clinical Toxicology 2006;44:525-6. Poster presentation: EAPCCT Prague 2006.
 89. Systematic collection of data on poisoned patients using a purpose-designed electronic database improves patient care. Greene SL, Dargan PI, Wood DM, Jones AL. Oral Presentation (Greene SL), 5th APAMT (Asia Pacific Association of Medical Toxicology) Meeting, Colombo Sri Lanka. August 2006
 90. Diagnosis of poisoning of unknown origin: a practical approach to the drowsy patient in a resource poor setting. Gawarammana IB, Dargan PI, Greene SL, Jones AL. Oral presentation (Gawarammana IB), 5th APAMT Meeting, Colombo, Sri Lanka, August 2006
 91. Herbal remedies and risk of lead poisoning, encephalopathy, polyneuropathy and anaemia: three cases. Dargan PI, Gawarammana IB, House IM, Jones AL. Oral presentation (Dargan PI), 5th APAMT Meeting, Colombo, Sri Lanka, August 2006
 92. Detection of flunitrazepam following ingestion of 1mg in healthy volunteers. Wood DM, Greene SL, Dargan PI, Morris P, Gawarammana IB, Streete P, Jones AL. Clinical Toxicology 2006; 44: 629-630. Poster presentation: NACCT San Francisco, October 2006.
 93. Intravenous N-acetylcysteine increases INR in the absence of significant acetaminophen hepatotoxicity. Greene SL, Wood DM, Dargan PI, Gawarammana IB, Jones AL. Clinical Toxicology 2006; 44: 629. Poster presentation: NACCT San Francisco, October 2006.

94. Education provides sustained improvement in doctors knowledge of methods of gut decontamination.
Wood DM, Greene SL, Dargan PI, Jones AL.
Clinical Toxicology 2006; 44: 641.
Poster presentation: NACCT San Francisco, October 2006.
95. Epidemiology of poisoning presentations to a large urban emergency department.
Greene SL, Dargan PI, Wood DM, Gawarammana IB, Jones AL.
Clinical Toxicology 2006; 44: 649-650
Poster presentation: NACCT San Francisco, October 2006.
96. Does ethanol coingestion affect outcome in acute acetaminophen overdose.
Greene SL, Dargan PI, Wood DM, Gawarammana IB, Jones AL.
Clinical Toxicology 2006; 44: 659
Poster presentation: NACCT San Francisco, October 2006.
97. Adverse reactions to intravenous N-acetylcysteine in the treatment of acetaminophen poisoning.
Greene SL, Dargan PI, Wood DM, Gawarammana IB, Jones AL.
Clinical Toxicology 2006; 44: 679-680
Poster presentation: NACCT San Francisco, October 2006.
98. *In vitro* studies with a novel granular activated charcoal.
Dargan PI, Melillo M, Wood DM, Jones AL, Mikhailovsky SV.
Clinical Toxicology 2006; 44: 686-687
Poster presentation: NACCT San Francisco, October 2006.
99. Intraoperative mercury concentrations during surgical removal of extensive subcutaneous elemental mercury deposits.
Dargan PI, Greene SL, Wood DM, Hunt D, House IM, Jones AL.
Clinical Toxicology 2006; 44: 688-689
Poster presentation: NACCT San Francisco, October 2006.
100. Development of a national antidote stock guideline for EDs in the UK.
Dines AM, Dargan PI, Dev S, Collignon U, Jones AL.
Clinical Toxicology 2006;44:726-7.
Poster presentation: NACCT San Francisco, October 2006.
101. Doctors know that cocaine is a risk factor for acute coronary syndrome, but don't routinely ask about it in clinical practice.
Wood DM, Hill D, Gunasekera A, Greene SL, Jones AL, Dargan PI.
Clinical Toxicology 2006; 44: 742
Poster presentation: NACCT San Francisco, October 2006.
102. Safety of high-dose insulin therapy in calcium channel antagonist overdose.
Greene SL, Gawarammana IB, Dargan PI, Wood DM, Jones AL.
Clinical Toxicology 2006; 44: 758
Poster presentation: NACCT San Francisco, October 2006.
103. Paediatricians have greater knowledge of methods of gut decontamination and greater use of gut decontamination in clinical practice.
Wood DM, Greene SL, Dargan PI, Jones AL.
Clinical Toxicology 2006; 44: 760
Poster presentation: NACCT San Francisco, October 2006.
104. Paraquat poisoning: caution interpreting prognosis based on plasma paraquat concentrations.
Dargan PI, Shiew CM, Greene SL, Gawarammana IB, Jones AL.
Clinical Toxicology 2006;44:762-3.
Poster presentation: NACCT San Francisco, October 2006.
105. Methanol elimination kinetics during hemodiafiltration: a case report.
Wood DM, Dargan PI, Navqi R, Quinlivan FP, Jones AL.
Clinical Toxicology 2006; 44: 764
Poster presentation: NACCT San Francisco, October 2006.
106. Status epilepticus following ingestion of fluvoxamine: a case report with serum fluvoxamine concentrations.
Wood DM, Rajalingam Y, Greene SL, Morgan PE, Gerrie D, Jones AL, Dargan PI.
Clinical Toxicology 2006; 44: 767
Poster presentation: NACCT San Francisco, October 2006.
107. Greene SL, Dargan PI, Wood DM, Jones AL.
Development of an electronic clinical toxicology database as a tool to increase the knowledge base in clinical toxicology.
Clinical Toxicology 2006; 44: 779-780
Oral presentation (Greene SL): NACCT San Francisco, October 2006.
108. Wood DM, Archer JA, Tizzard Z, Jones AL, Dargan PI.
Alcohol hand rubs: balancing hygiene with the risk of hazard.
Clinical Toxicology 2007; 45: 642
109. Wood DM, Greene SL, Ovaska H, Archer JR, Jones AL, Dargan PI.
Doctors knowledge of the appropriate use of specific antidotes in recreational drug poisoning.
Clinical Toxicology 2007; 45: 616
110. Wood DM, Dargan PI, Button J, Holt DW, Ovaska H, Ramsey J, Jones AL.
Cluster of 1-Benzylpiperazine poisonings presenting to an emergency department. Clinical Toxicology 2007; 45: 624
111. Dargan PI, Wood DM, Drake N, Jones AL, Greene SL.
Improved management of poisoned patients through the use of prospective clinical audit.
Clinical Toxicology 2007; 45: 634
112. Wood DM, Warren-Gash C, Greene SL, Jones AL, Bishop C, Shather Z, Dargan PI.
Case series of 150 GHB poisonings seen at a large inner-city teaching hospital in 2006.
Clinical Toxicology 2007; 45: 627-628
113. Dargan PI, Bishop C, Jones AL, Wood DM.
Medical students knowledge of drugs of abuse.
Clinical Toxicology 2007; 45: 609

114. Greene SL, Wood DM, Jones AL, Dargan PI.
Safety of naloxone administered in the emergency department.
Clinical Toxicology 2007; 45: 613
115. Risk Communication. Hunter New England Health Quality Exposition and Scientific Program. October 2007. Keynote Lecture.
116. Change Champions Congress. Keynote lecture – MS-SQL - Developing an area quality use of medicines committee. Melbourne, 2008.
117. World Health Day Lecture. “Lessons of managing lead contamination in Esperance”, Perth, WA. April 2008
118. Prime Minister and Cabinets Office Canberra. UK resilience issues in chemical terrorism. August 2008
119. NAACT Keynote lecture. Jones AL. Assessing the evidence...Toronto, Canada.
120. New Institute. Newcastle. Jones AL, Experiences from attending Prime Minister’s 2020 summit in Canberra.
121. Jones AL. “Risk Communication in chemical terrorism”. Department of Homeland Security Network 2008. Washington D.C. Keynote lecture.
122. Senior Hospital Pharmacists Association Annual Meeting. Keynote lecture on “chemical terrorism”. November 2008. Sydney.
123. Hunter Postgraduate Medical Institute. November 2008. Neuroleptic malignant syndrome and serotonin toxicity.
124. Jones AL, Sax Institute Keynote lecture on “Toxicology Matters” at Health Policy and Research Exchange, November 2008.
125. Jones AL, “Paediatric toxicology” talk to regional paediatricians at the John Hunter Hospital Newcastle. December 2008
126. Paediatric Research Network for Clinical Trials. Office State Medical Research. Sydney. December 2008.
127. Wood DM, Aldus G, Greene SL, Lovitt C, Heather K, Jones AL, Drake N, Dargan PI. Development of the P-CAP (Poisoned Clubbers Avoidance Project) ambulance referral guidelines.
Clinical Toxicology 2008; 46: 393
Poster presentation: EAPCCT Seville, Spain May 2008
128. Jones AL. Journals critical appraisals. Keynote Sessions NAACT Meeting Toronto, Canada. September 2008.
129. Wood DM, Button J, Ovaska H, Jones AL, Holt DW, Ramsey J, Dargan PI.
A series of emerging novel recreational drugs - a potential problem for the future. *J Med Toxicol* 2008; 4: 303
Oral presentation by David Wood: 6th Asia Pacific Association of Medical Toxicology Meeting: Bangkok, Thailand, December 2008.
130. Jones AL. Keynote lectures on “updates in the management of paracetamol poisoning” IECM Congress Dubai. Also keynote lectures on “What’s new in paracetamol poisoning”, “Assessment and management of the poisoned patient in the ED” and “How to develop a poisons centre” at the Middle East North Africa Toxicology Symposium Dubai. April 2009.
131. NACCT 2010 Denver, Colorado. “Incomplete recovery of cognitive functions in patients discharged following sedative drug overdose”. Platform Session IV 11th Oct 2010 – abstract published in *J Clin Tox* 2010. Also keynote lecture on ‘Publications you may have missed’.
132. AUCEA National Conference, 5-7th July, Launceston, Tasmania. Partnership engaging for Health: Medicine in Context as a case study in engaged teaching and learning for students in medicine.
133. NAACT 2011 Washington DC. ‘Articles you might have missed’ – a RCA review of controversial articles in *Clinical Toxicology*. Jones AL. Keynote address.
134. Andersen P, Tait N, Walsj K, Gaetani P, Jones AL, Brown A.
Ward rounds: developing a collaborative best practice model of interdisciplinary teaching for multidisciplinary practice.
Sim Health 2012: Making teams work, Sydney Australia: Australian Society for simulation in healthcare. Conference publication.
135. Keynote lecture on toxicology, participation in debating team “does law protect vulnerable populations?”
Australian-Greek Society of Medicine and Law
Cape Sounion, Athens 2013
136. Keynote lecture for the NACCT Annual Meeting 2013 Jones AL, Morgan J. The case for high dose naloxone. North American Congress of Clinical Toxicology (NAACT) 10th-16th October 2017; Vancouver, Canada. [KEYNOTE ADDRESS]
137. Jones AL, Morgan J. The toxicology of drug-facilitated sexual assault. Royal College of Pathologists of Australasia (RCPA) Pathology Update 2nd-4th March 2018; Sydney, Australia. [KEYNOTE ADDRESS]
138. Jones AL, Morgan J. Pharmacological Approaches to Posttraumatic Stress Disorder. FearLess National Conversation on PTSD 2019, 21st-23rd August 2019; Sunshine Coast, Caloundra, QLD, Australia